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“There is no comparison between that which is lost by 
not succeeding and that which is lost by not trying”
Sir Francis Bacon (1561-1626)

1 
 
Index 
 
Acknowledgements           3 
Abstract in Norwegian          7 
Abbreviations            9 
Publications included          10 
 
1. General introduction         12 
 
2. Background  
2.1 Stroke 
 
2.1.1 Definition of stroke      14 
2.1.2 Incidence of stroke      14 
2.1.3 Diagnosis of stroke      15  
2.1.4 Treatment of acute stroke     16 
2.1.5 Classification of stroke     18 
2.1.6 Classification of neurological and functional            
impairments in stroke     19 
2.1.7 Risk factors for stroke     20 
2.1.8 Secondary prevention after stroke    21 
2.1.9 Cognitive impairments after stroke    25 
2.1.10 Assessments for cognitive impairments after stroke 26 
2.1.11 Prognosis after stroke     27 
 
2.2 Dementia and Mild Cognitive Impairment (MCI) 
 
2.2.1 The cognitive impairment in dementia   29 
2.2.2 Mild Cognitive Impairment (MCI)    29 
2.2.3 Prevalence of dementia      29 
2.2.4 Etiology of dementia      30 
2.2.5 Diagnosis of dementia     30 
2.2.6 Diagnosis of MCI      30 
2.2.7 Diagnosis of dementia due to Alzheimer’s disease (AD) 31 
2.2.8 Diagnosis of Vascular Dementia (VaD)   31 
2.2.9 Diagnosis of vascular cognitive impairment  32 
2.2.10 Neuroimaging      32 
2.2.11 Risk factors of dementia      33 
2.2.12 Prevention and treatment of dementia   33 
 
3. Aims of the thesis         35 
 
4. Methods 
 
4.1   Participants         36 
4.2   Assessment  
  4.2.1 Assessment at baseline      37 
  4.2.2 Assessment at 3 and 6 month     38 
  4.2.3 Assessment at the 12 month follow-up   38 
4.3   Baseline characteristics       38 
2 
 
4.4   Methods in the TOAST study, paper 1     40 
4.5   Methods for the intervention study, paper 2    41 
4.5.1 Intervention       41 
4.5.2 Outcome in the RCT      42 
4.6 Methods in the MCI/dementia study, paper 3 
4.6.1 Evaluation of cerebral MRI     42 
4.6.2 Subclassification of cognitive impairments post-stroke 42 
4.7 Methods of the WML study, paper 4     43 
 
5. Statistics          44 
6. Ethical considerations        45 
7. Abstracts of papers included in the thesis      46 
8. General discussion         50 
8.1 Methodological considerations 
8.1.1 Patients        50 
8.1.2 Methods        51 
8.1.3 Intervention        52 
8.1.4 Statistics        53 
8.2 The TOAST study        53  
8.3 The intervention study        53 
8.4 The MCI/dementia study        55 
8.5 The WML study         55 
8.6 Final comments         56 
8.7 Suggestions for further research       57 
9. Conclusions          58 
10. References          59 
11. Papers                            77 
 
 
 
 
 
 
 
 
 
  
3 
 
 
Acknowledgements 
 
This study had not been possible without the positive attitude of the patients who participated 
in the study. With only a few exceptions, most patients were willing to contribute and devote 
their time and efforts to complete the intervention and follow-up. An acute stroke is a major 
life-changing event for the person involved; I have deep respect and gratitude for the 
generosity of these patients, who participated in this research during a challenging and 
stressful period of their lives. I am impressed by the ability of these patients to maintain 
motivation for long-term rehabilitation and by the way they gracefully accept and adjust to 
their altered life circumstances. 
 
The present work has been carried out in the Department of Geriatric Medicine, Stroke and 
Rehabilitation, Bærum Hospital, Vestre Viken Hospital Trust. The project was made possible 
by financial support by Helse SørØst, Vestre Viken Hospital Trust and the Foundation for 
research in internal medicine and through my position as a consultant geriatrician in the 
outpatient clinic. As a research fellow in a local hospital, I was dependent on close 
cooperation with the University of Oslo. I am grateful for all the support.  
 
Working with this thesis has made me a better doctor, a more critical reader of scientific 
publications, and a person with greater humility and respect for medical research and for the 
patients’ involved. I have learned a lot throughout the whole process: from the idea taking 
shape and planning the project, applying for grants, collecting the data, motivating patients for 
lifestyle changes, participating in sub studies, preparing and creating the database, performing 
the statistical analyses, and writing the manuscripts. I have become more competent in 
computer science and medical statistics and improved my English! I have become more 
fascinated by the complexity of the brain and the processes involved in normal and 
pathological aging. The take-home message is this: Stay physically fit and be intellectually 
curious!  
 
First, I would like to thank my supervisors for their support throughout the last 6 years. They 
have all been involved in all phases of the project, from the idea to the manuscripts, and they 
have given me the greatest support.  
 
My deepest thanks are owed to the following individuals: 
 
Brynjar Fure, for initiating the project, for your concern for patients suffering from stroke 
and cognitive impairment, for encouraging the multidisciplinary team to do research in order 
to improve the care and for sharing your knowledge in stroke and research. You have been my 
mentor and friend, always available and always enthusiastic and encouraging. You have 
proofread and edited many drafts of articles and lecture presentations.  You have also been a 
listening ear and supported me through the ups and downs of my life, both professionally and 
personally. You see opportunities and solutions and have a great capacity for work. 
 
Bente Thommessen, for your wisdom, presence, and for having a big heart for both patients 
and colleagues. You contributed so much scientifically and worked so hard in the consensus 
group.  I have really enjoyed working with you and appreciated the valuable discussions. 
 
4 
 
Torgeir Bruun Wyller, professor, for your work ethic, your broad knowledge in geriatric 
medicine and research, for scientific discussions, for constructive criticism and for always 
being supportive. Your responses to emails are immediate! You have edited the entire 
manuscript several times. I admire your unique enthusiasm for the complexity of geriatric 
medicine and research and for your ability to get to the root of the matter. 
 
Knut Engedal, professor, for all your knowledge in dementia and assessment of cognitive 
function, for communicating a positive attitude toward persons with cognitive impairment, for 
the ability to find the weak spots, for your help in making me more systematic in the 
discussion parts of all the manuscripts, and for inspiring me to give presentations and 
contribute in scientific networks.  You have always motivated me and been a pillar of support.   
 
Anne Rita Øksengård, for all your enthusiasm for dementia research, for including me in 
research groups, encouraging me to join the EAMA, for doing a great job in the consensus 
group and for introducing us to Kirsti Løken. You are an inspirational person, clinician and 
researcher.   
 
 
I also want to express my gratitude towards the following collaborators: 
 
Morten Wang Fargerland, for your indispensible help regarding statistical analyses in two 
of the articles, for talking statistics in a way that is possible to understand and for taking so 
much responsibility in the work. You have been very flexible and positive. I hope we can 
continue to cooperate.  
 
Kirsti Løken, an experienced radiologist, for international cooperation regarding evaluation 
of the medial temporal lobe, and for doing all the measures of the MTLA. 
 
Vidar Stenset, a neurosurgeon with great knowledge regarding white matter changes in the 
brain, for evaluating all the MRI scans for vascular changes. 
 
Audhild Tørstad and Marie Ursin, physiotherapists, and Else Graven, occupational 
therapists, for doing sub-studies regarding balance and cognition. They have all completed 
Master’s degrees.  And thanks to Nadine Probst and Anne Wergeland, both specially 
trained nurses in the stroke unit, for their special attention towards the young stroke patients 
and their involvement in the study recruitment and assessments. You all inspire and improve 
the work in our unit. 
 
Special thanks to: 
 
*All my co-workers and colleagues in the stroke unit for their support, for helping to recruit 
patients and for continually striving to improve the care for stroke patients. A special thanks 
to Inger Vandvik for her involvement in the acute stroke care including thrombolytic 
therapy. 
 
*All the staff working in the ward for being so enthusiastic about the project, making all the 
assessments and taking such good care of the patients. I am proud of the quality of care given 
to the patients in our unit. 
 
5 
 
*Kari Wie Skar, for knowing everything about everybody in the project and helping the 
patients during their stay in the outpatient clinic, and for being a caring friend.  You are 
indispensable! 
*Anne Mette Brenden, for doing all the tests in a way so that the patients felt secure and well 
looked after, and for your humour and your positive attitude. We have had such a good time 
with a lot of laughs.  
 
*Gro Vik Knutsen, Kristin Staib, Mai Bente Myrvold, Knut Erling Moksnes, Gyrid 
Gjerde, Niels Kristian Thybo and Britt Eidsvoll, for enthusiastic and encouraging support 
as my leaders and for positive attitudes towards clinical research. Gyrid, you have been a 
driving force behind this project. You saw the possibilities! And Gro, you are a great 
colleague and friend. 
 
*The MRI department, for taking cranial MRI scans of all patients at follow-up.  Excellent 
service! 
 
*My colleges in the Research Unit (Loftet), for encouragement to do geriatric research and 
inspiring lectures. Anne Garmark, an extra thanks to you for doing the randomisation and 
for being helpful and concerning. A special warm thanks to Siri R Kristjansson, for being a 
supportive friend with an interest in running, and to Anne K Gulsvik, for being a good friend 
with a great sense of humor. Both have a curiosity for geriatric medicine and older patients.  
 
*Medical Research Department, for including me in the last phase of the project. I needed 
the mental support and the friendships and I have enjoyed being part of the group. I am 
impressed by the number and quality of ongoing projects and that Bærum Hospital has 
managed to build up a dedicated research department. Arnljot Tveit is a mentor, a gifted 
teacher, and a source of inspiration. Steve Enger, you have helped me so many times with 
computer problems. And Mona Olufsen, I have finally completed the fire safety course 
online! Thank you for looking after me! Trygve Berge, it has been a pleasure to share office 
space with you! And Sarah Kaldestad, thank you so much for all the help with my English!  
I look forward to continued research collaboration with the department.    
 
*My colleagues at the Department of Internal Medicine, especially Else Johanne Rønning 
and Jan Svendsen, my nearest co-workers every day.  
 
*Gitta, thank you for making me happy.   
*Helene, Johan August and Ingeborg, thank you for your love, support and patience. You 
make me proud and fill me with joy.  
 
 
. 
 
 
 
 
 
 
 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Norsk sammendrag 
 
Bakgrunn 
Behandling av modifiserbare risikofaktorer gjøres som ledd i primærprofylakse og 
sekundærprofylakse for å forebygge hjerneslag. Hjerneslag er den tredje hyppigste 
dødsårsaken i Norge, og den vanligste årsaken til alvorlig funksjonshemning der mange lever 
med fysiske og mentale endringer som følge av et hjerneslag. 
 
Demens etter hjerneslag er definert som demens som oppstår etter et slag, og inkluderer 
vaskulær demens, degenerative demens (oftest Alzheimers sykdom) og blandingsdemens 
(både vaskulære og degenerative forandringer). Vaskulære risikoaktorer bidrar ikke bare til 
vaskulær demens, men synes å påvirke kaskaden i Alzheimer patologi som utvikles til 
demens. 
 
Vi ønsket å undersøke om intensiv multifaktoriell karforebyggende behandling kunne 
forebygge kognitiv svikt etter hjerneslag. Vi ønsket å se på fordelingen av ulike sub-grupper 
av iskemiske hjerneslag og innbyrdes assosiasjon til vaskulære risikofaktorer. Videre ville vi 
undersøke insidensen av demens og mild kognitiv svikt etter hjerneslag med mulige 
etiologiske mekanismer. Vi evaluerte også assosiasjonen mellom kroniske 
sirkulasjonsforandringer i hjernen (White Matter Lesions=WML) og pasientens prestasjoner 
på kognitive tester.    
 
Metode 
227 pasienter med sitt første hjerneslag eller TIA (drypp) uten kjent kognitiv svikt innlagt i 
slagenheten, Bærum Sykehus, Vestre Viken HF, ble inkludert. Vaskulære risikofaktorer ble 
registrert, hjerneslaget klassifisert og nevrologiske og kognitive utfall målt. De primære 
endepunktene var TMT A og 10-ords-test, som måler henholdsvis tempo og oppmerksomhet 
og hukommelse. Etter utreise ble pasientene randomisert til å komme til konsultasjoner i vår 
slagpoliklinikk for intensiv karforebyggende behandling, eller gå til vanlig oppfølging hos 
fastlegen.  
 
Intervensjonen besto i å forsøke å nå følgende behandlingsmål:   
1. Blodtrykk til <140/90 
2. Total-kolesterol <5 og LDL <3 
3. Røykekutt 
4. For diabetikere langtids-blodsukker (HBA1c) <7.0 
5. Homocystein < 15 
6. Fysisk aktivitet minimum 30 min x3 pr uke 
7. BMI < 25 
8. Kost inneholdende mer frukt og grønt, mer frukt, mindre mettet fett og karbohydrater 
9. Høyt alkoholkonsum (> 2-3 enheter daglig) anbefales ikke 
 
Alle ble innkalt til kontroll 1 år etter hendelsen. Her ble igjen kar risiko registrert og 
kognisjonen og nevrologiske følgetilstander målt. Alle fikk tilbud om MR av hodet og 
spinalpunksjon.  
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Resultater 
Vi klarte ikke å vise at intens karforebyggende behandling påvirket utviklingen av 
hukommelsesvansker etter hjerneslag eller TIA. 
 
Hele 31.4 % av pasientene med iskemiske hjerneslag hadde småkarsykdom som etiologisk 
diagnose, mens kun 11.4 % hadde slag på bakgrunn av storkarsykdom. Hyperlipidemi 
(Kolesterol >5 og/eller LDL > 3) og røyking var relatert til småkarsykdom. 
 
57.1 % utviklet hukommelsesforandringer som ledd i demens eller mild kognitiv svikt 1 år 
etter sitt første hjerneslag. Kun 13.3 utviklet demens på rent vaskulært grunnlag, mens over 
halvparten utviklet kognitiv svikt grunnet kombinasjonen av vaskulære og degenerative 
forandringer.   
 
TMT A og 10-ords-test var signifikant assosiert med WML, og de var også signifikant 
assosiert med atrofi av mediale temporallapp (MTLA).   
 
Konklusjon  
Vi klarte ikke å vise at intensiv multifaktoriell karforebyggende behandling forebygget 
kognitiv svikt etter hjerneslag. Til dette var oppfølgingstiden for kort og variasjonene innad i 
gruppene for stor. 
 
Vi observerte en endring i fordelingen av etiologiske sub-grupper av iskemiske hjerneslag 
med hyppigere småkarsykdom og mindre hyppig storkarsykdom. Småkarsykdom var 
signifikant assosiert med høyt kolesterol og røyking. 
 
Blant første gangs hjerneslag og TIA uten kjent kognitiv svikt utviklet 57 % 
hukommelsesvansker 1 år etter slaget, og kun en tredjedel på rent vaskulært grunnlag. 
Sameksistensen av vaskulære og degenerative forandringer var betydelig. 
 
Eksekutiv svikt og hukommelsesproblemer etter hjerneslag er assosiert med kroniske 
sirkulasjonsforandring. Mekanismene involvert i kognitiv svikt etter hjerneslag skyldes en 
kombinasjon av degenerative og ulike vaskulære forandringer.  
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Hippocrates (460-370 BC) credited the brain with intelligence and thought.  
 
 
 
 
 
 
 
 
 
Alf Brodal, a 62-year-old professor in anatomy and a pioneer in neurobiological science, 
suffered a presumed classical launar stroke with left-sided hemiparesis. He describes his own 
experience in a scientific paper published in Brain, 1973 (1):  
 
“Subjectively, the patient noted that he became much more easily tired than previously from 
mental work, even from ordinary conversation and reading newspapers. There was a marked 
reduction in the powers of concentration which made mental tasks far more demanding than 
before. Reading novels did not cause great problems, but it was often quite difficult and 
needed much concentration to follow the arguments, for example in a scientific paper. In part, 
this seemed to be due to a reduced capacity to retain the sense of a sentence long enough to 
combine it with the meaning of the next sentence. It appeared subjectively as a reduction of 
short-term memory for abstract symbols. This is supported by the following observation: 
when trying to remember a series of figures, for example looking reference numbers up in a 
list, the limits of achievement even with maximal concentration were reduced, compared with 
previous capacity. These few observations, along with some others of a similar type, suggest 
that there is some impairment of certain mental functions.” 
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1. General introduction: 
 
Every other second a person suffers a stroke worldwide (2). Because of the aging population, 
the burden of stroke will increase greatly (3). Stroke is a common disorder in Norway, and 
around 15.000 people have a stroke each year (4). Stroke is a major cause of disability, and  is 
the third most common cause of death. One year after stroke almost one third of the survivors 
are functionally dependent (5). The thirty-day mortality in ischemic stroke is reduced to 2.8% 
in Norway in 2009, compared to 6.1% in 2000 (6).  
 
Cognition, from the Latin term cognoscere, means "to know", "to conceptualize" or "to 
recognize". Cognition includes attention, remembering, producing and understanding 
language, solving problems, and making decisions. Cognitive function includes how we use 
information, think, learn, judge, apply knowledge and change preferences. Dementia is 
described as an acquired cognitive impairment with affected emotional control and impaired 
function in daily life (7). Cognitive disturbances are frequent after stroke, but rates regarding 
post-stroke dementia and cognitive impairments vary from 7.4 to 56.3 % (8). 
 
Acute stroke is an acute illness and a “brain-at-risk” condition, and the patient is in need of 
acute hospitalisation for the diagnosis, acute treatment and early rehabilitation. Stroke 
treatment is a rapidly advancing field. Interventions like management of patients with acute 
stroke in stroke units, intravenous tissue plasminogen activator within 4.5 hours of stroke 
onset and decompressive surgery for supratentorial malignant hemispheric cerebral infarctions 
are of benefit. Regarding secondary prevention, we use anticoagulation for patients with atrial 
fibrillation, perform endarterectomy for symptomatic carotid stenosis and give antiplatelet 
agents and statin therapy. For stroke prevention, there are two main strategies. The 
“population” approach aims to reduce stroke by lowering the prevalence with public 
education and government legislation (9). The “high risk” approach aims to reduce stroke by 
identifying individuals at high risk of stroke and lowering their risk with optimal medical 
therapy and lifestyle advices.  
 
In the last decades, there has been a change in the epidemiology regarding life style and risk 
factors for cognitive impairment. When we compare persons aged 70 years in 2000 with 
persons aged 70 years in 1970, the first group has better cognitive function, higher 
educational level and tend to smoke less and be more often obese (10). Likewise, an 85-year-
old in 2008 versus 1986 seems to suffer from less dementia but has a higher prevalence of 
stroke (Skoog I, personal message). Better pre-stroke control of vascular risk factors and 
better survival and functional outcome as an effect of the stroke unit and thrombolytic therapy 
for acute ischemic stroke may preserve cognitive functioning after stroke.   
  
Post-stroke dementia is defined as any dementia occurring after stroke, and includes vascular 
dementia (VaD), degenerative dementia (mostly Alzheimer’s disease, AD) and mixed 
dementia (coexistence of vascular and degenerative changes). Vascular risk factors contribute 
not only to vascular dementia, but probably also in the cascade of Alzheimer pathology 
proceeding to clinical dementia (11). 
 
In addition to a shift in lifestyle-related vascular risk factors, there is a shift in the approach to 
dementia. Cognitive impairment can be considered as a continuum which affects different 
cognitive domains, and with different causes. These often include the coexistence of vascular 
and degenerative changes (12). Further, both AD and cerebrovascular diseases share the same 
risk factors, most of them treatable. Identification and treatment of vascular risk factors 
13 
 
prevent stroke, and probably, cognitive impairment as well. Prevention of cerebrovascular 
disease may significantly impact the incidence of cognitive decline and dementia in the 
elderly.  
 
The present study evaluated different aspects regarding post-stroke cognitive impairments; 
prevalence, risk factors, etiology, neuroimaging and prevention. For the intervention study, 
we hypothesized that a multifactorial vascular risk factor intervention would reduce the 
incidence of cognitive impairment post-stroke.  
 
Our findings may have clinical implications regarding vascular risk factor management post-
stroke, for prediction of cognitive decline in stroke patients and for the understanding of the 
coexistence of vascular and degenerative changes in post-stroke cognitive impairment. 
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2. Background  
2.1 Stroke 
2.1.1 Definition of stroke  
The definition of stroke used by the World Health Organization is a syndrome of rapidly 
developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms 
lasting 24 hours or longer or leading to death, with no apparent cause other than of vascular 
origin (13). Stroke is, per definition, a clinical syndrome. A TIA implies the acute loss of 
focal cerebral function with symptoms lasting less than 24 hours (14). Due to Magnet 
Resonance Imaging (MRI) findings in almost 50 % of the TIA patients and permanent tissue 
damage in at least 25% of them (15), the definition of TIA is under revision, proposing a new 
definition including symptoms caused by focal brain ischemia without acute infarction (16).  
 
2.1.2 Incidence of stroke 
The incidence of stroke is defined as the number of first in a life-time strokes occurring per 
unit time. In Norway, there is 11.000 first-ever strokes per year (4). At every age, rates for 
men are higher (17). But due to longer life-expectancy for women, they suffer more strokes in 
total (18). Almost one in four men and nearly one in five women aged 45 years can expect to 
have a stroke if they live to their 85th year (5). The converse is true for life-time risk of dying 
from stroke. About 16% of all women are likely to die of a stroke compared with 8% of the 
men due to the higher mean age at stroke onset in women and greater life expectancy.  
 
The number of patients suffering from stroke will increase considerably during the next 
decades (19). Figure 1 shows the expected rise in stroke cases in Norway. In 20 years, there 
will be an almost 50%  increase in stroke. However, if preventive measures are implemented 
among all Norwegians, these figures will be lower. 
 
Figure 1. Incidence of stroke in Norway 
 
 
From Scenario 2030, Statens Helsetilsyn (19). 
 
In Norway, 55.000 persons live after stroke today (20).  
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The risk of a recurrent stroke is 10% within 7 days, and 18% within 3 months (Figure 2) (21). 
 
Figure 2: Cumulative risk of stroke after transient ischemic attack (TIA) or minor stroke  
 
 
Coull, BMJ 2004 (21). 
 
2.1.3 Diagnosis of stroke 
Clinically, stroke is characterized by a rapid onset of focal symptoms such as hemiparesis, 
sensory loss, facial paresis, dysarthria or diplopia. Stroke affecting cerebellum may lead to e.g 
ataxia. Affection of the cortex of the left hemisphere may lead to aphasia, apraxia and 
agnosia, while stroke in the area of right cortex may affect orientation, attention and self 
awareness.  
 
Early clinical evaluation, including physiological variables and routine blood tests, is 
recommended (22). Evaluation of neurological deficits (using National Institutes of Health 
Stroke Scale (NIHSS) score) should be obtained and imaging performed without delay. 
   
A computer tomography (CT scan) of the brain can diagnose a cerebral hemorrhage almost 
immediately after onset of symptoms (23). Cerebral infarctions, on the other hand, can be 
visualized on CT scans from a few hours to over 48 hours after onset of symptoms. In almost 
50% of the cases, there will be signs on CT scans 6 hours after ictus (24). MRI and CT scans 
have similar accuracy in detecting intracerebral hemorrhage in the acute phase (25). 
 
Positron Emission Tomography (PET) and MRI techniques including T2 weighted scans as 
well as diffusion-weighted (DW) and perfusion-weighted (PW) techniques show cerebral 
infarctions at a very early stage, and may even visualize the ischemic penumbra in the brain 
before a permanent infarction has developed (26). This penumbra refers to the tissue with 
preserved neuronal integrity, but due to hypoperfusion, in risk of impairment (27). The larger 
the penumbra volume and the smaller the ischemic infarct core, the greater the potential 
benefit with reperfusion therapy (28). 
 
Due to limited resources regarding MRI, most hospitals treat acute stroke patients and offers 
trombolysis without an MRI in the acute phase. However, most hospitals offer CT 
angiography for detection of the embolus prior to trombolysis and endovascular re-
canalization therapy.   
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For the detection of the source of an embolus or an internal carotid artery dissection and for 
optimal secondary prevention, patients undergo a duplex of the precerebral arteries. For 
stenoses 70-99% this non-invastive test has high sensitivity and specificity (29). In addition to 
evaluation of a stenosis, color duplex of precerebral arteries visualizes the Intima Media 
Tickness (IMT) and atherosclerotic plaques (30), especially ruptures of the plaques. The 
intracranial arteries (the middle cerebral artery (MCA), the anterior cerebral artery (ACA), the 
posterior cerebral artery (PCA) and the communicants), can be visualized through 
transcranial, especially transtemporal, color duplex images (31). Transcranial duplex 
investigations may be technically difficult to perform, as the transtemporal window, in 
particular in older persons, can be hard to locate (32). Revascularisation of the MCA can be 
evaluated by repeating transcranial duplex after thrombolysis (33). Transcranial Doppler can 
also be used for cerebral microemboli detection (34), including artery-to-artery embolisation 
and cardiac embolisation.    
 
Embolism from the heart results in almost 30% of all cerebral infarctions. All patients should 
perform a 12-lead electrocardiography (ECG) in the acute phase in order to detect atrial 
fibrillation (AF) and signs of acute ischemic heart disease. 24-hour Holter ECG monitoring 
should be performed when arrhythmias are suspected and no other causes of stroke are found 
(ESO 2008). Transthoracic echocardiography (TTE) in patients with acute stroke is 
recommended when clinical evidence of cardiac disease by history, physical examination, 
electrocardiography or chest radiography is present (35). Routine echocardiography is not 
recommended for patients with clinical cardiac disease who have independent indication for 
or contraindications to anticoagulant therapy. Transeosophageal echocardiography (TEE) is 
regarded superior to TTE in identifying a cardiac embolic source (36), in particular the 
detection of a thrombus in the the left artial appendage, patent foramen ovale and aortic 
atheroma (37). 
 
Trombophilic conditions including antiphospholipid antibodies and inherited thrombophilias 
(deficiencies of the natural anticoagulants antithrombin III, protein S and C and mutations in 
factor V Leiden and factor II) are associated with vascular occlusive events. Routine 
screening is not recommended, since coagulation disorders is the cause in a minority of 
ischemic strokes, and may be considered only among young patients with non-cardioembolic 
stroke (38). 
 
In cerebral haemorrhage, arteriovenous malformations and bleeding in relation to tumours 
should be excluded. 
 
2.1.4 Treatment of acute stroke 
The treatment of acute stroke is evolving. The treatment includes reducing the mortality and 
morbidity of the acute event and preventing subsequent events. 
 
Patients with spontaneous supratentorial intracerebral hemorrhage show no overall benefit 
from early surgery when compared with initial conservative treatment (39). 
 
Treatment of acute ischemic stroke has primarily two initial approaches: limitation of the 
ischemic insult by early reperfusion (the vascular approach) and interference with the 
pathobiochemical cascade leading to ischemic neuronal damage (the cellular approach) (40). 
In addition, complication prevention and early rehabilitation are of importance. Treatment in 
stroke units improves survival and functional state, and the effect lasts for at least 10 years 
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(41). Reperfusion treatments have been a success, and are associated with improved clinical 
outcomes, but neuroprotective strategies have failed to show clinical benefit (42). 
 
Patients with acute stroke need both acute care and acute rehabilitation. A stroke unit (SU) is 
dedicated to both of these elements, and has strong evidence of effectiveness. Stroke units 
improve outcomes of patients with stroke (41). The SU consists of nurses, doctors and 
therapists, all specially trained in monitoring patients with stroke and working in coordinated 
teams. Patients with stroke who receive organized inpatient care in SU are more likely to be 
alive, independent, and living at home one year after stroke (43). Every hospital receiving 
patients with stroke should treat them in specialized stroke units. In addition, comprehensive 
centers are needed for more advanced neuroimaging and intra-arterial treatment. 
 
Antiplatelet therapy with aspirin 300 mg given orally within the first 48 hours reduces the risk 
of early recurrent ischemic stroke (44). It also increases the chances of being alive and 
independent with less neurological sequel. The risk of early hemorrhagic complications is 
low. 
 
Reperfusion induced by thrombolysis has been shown to be effective when initiated within 
4.5 hours of onset of symptoms (45). Odds of a favorable 3-months outcome is 2.8 (95 % CI 
1.8-4.5) for treatment ≤ 90 min, 1.6 (1.1-2.2) for 91-180 min and 1.4 (1.1-1.9) for 181-270 
min (46).  
 
In an acute stroke, the neurons in the infarction core die rapidly due to lack of oxygen (40), 
and only reperfusion strategies can increase the blood flow in the penumbra zone above the 
threshold where the nerve cells are irreversibly damaged. The penumbra zone has a 
therapeutic window extended to several hours. Intra-arterial trombolysis can be effective in 
treatment of acute stroke (47). Trombolysis is administrated selectively and directly through a 
catheter. For MCA occlusions, intra-arterial treatment given within 6 hours improved clinical 
outcome at 90 days (47). It may also be attempted in basilar thrombosis (48). Endovascular 
recanalization in acute ischemic stroke includes, in addition to intra-arterial thrombolysis, 
mechanical embolectomy by the use of endovascular devices and intra-arterial stents in order 
to revascularize occluded intracerebral arteries. Endovascular revascularization in stroke due 
to large vessel occlusion is described as safe and effective in patients within 8 hours from 
symptom onset (49-51). Recanalization is the strongest predictor for clinical outcome in 
patients having a thromectomy (52). Intra-arterial administration of thrombolytic agents and 
mechanical interventions has been promising, but due to limited data, additional research is 
need. In the meantime, carefully selected patients may benefit from the reperfusion approach 
(53).  
 
In patients with signs of malignant oedema, surgical hemicraniectomy must be considered 
(54).  
 
For optimal blood flow, the systolic blood pressure should be kept under 220 mm Hg and 
diastolic pressure under 120 mm Hg. Intravenous saline solution during the first 12 hours 
avoid dehydration and stabilize the blood pressure. Hyperglycemia is associated with poor 
outcome and should be avoided. Body temperature should be obtained normal (28). 
Complications should be detected early and properly treated. 
 
Anticoagulation is recommended in patients with AF for secondary prevention after 
cerebrovascular events (55;56). 
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Endarterectomy is of some benefit forpatients with 50% to 69% symptomatic carotid stenoses 
and highly beneficial in 70% to 99% stenoses without near occlusion (57), and should be 
performed within 14 days from onset of symptoms. 
 
2.1.5 Classification of stroke 
Strokes are either ischemic or haemorrhagic. 80-85 % of all strokes are ischemic stroke due to 
a thrombus or an embolus, 10-15 % are haemorrhagic strokes and <5% suffer from 
subarachnoid haemorrhage. This first differentiation is often made with CT scan, and is 
crucial as medical and surgical therapies differ in these groups.  
 
There are a number of classification systems of stroke, none of which are ideal. A 
classification system describing risk factors associated with the subtypes, which is important 
for secondary prevention, is missing. Systems for stroke classification have been made due to 
the needs of clinical trials (The Trial of Org 10172 in Acute Stroke Treatment (TOAST)) and 
epidemiological studies (the Oxfordshire Community Stroke Project (OSCP) classification). 
 
A useful clinically-based classification developed by Bamford (OSCP) (58) can be helpful 
when discussing prognostic aspects. This classification relies only on clinical findings. 
Cerebral infarctions are classified according to the topographic location and size of the 
cerebrovascular lesions. Total anterior circulation infarcts (TACI) have both cortical and 
subcortical involvement, partial anterior circulation infarcts (PACI) are more restricted and 
predominantly cortical infarcts, posterior circulation infarcts (POCI) are associated with the 
vertebrobasilar arterial territory and lacunar infarcts (LACI) are confined to the deep 
perforating arteries. LACI, i.e. small vessel disease with small deep infarcts due to occlusion 
of a penetrating artery, account for up to 25% of all ischemic strokes (59). TACI, traditionally 
affecting around 20% are associated with more dependency and higher mortality, PACI with 
higer risk of stroke recurrence earlier than POCI, and both LACI and POCI are associated 
with better outcome.  
 
The TOAST classification was introduced in 1993 to improve the subclassification of 
ischemic stroke (60). The TOAST criteria identify the most probable pathophysiological 
mechanism on the basis of the clinical neurological examination and results of paraclinical 
findings. Differentiation among etiological subgroups of cerebral infarction has therapeutic 
implications, and makes it easier to predict prognosis. The TOAST classification divides 
patients with ischemic stroke into five subgroups according to the presumed etiological 
mechanism that lead to vessel occlusion: cardio embolic disease, large vessel disease, small 
vessel disease, unusual causes of stroke and stroke of undetermined etiology. Stroke of 
unusual etiology is caused by mechanisms such as hypercoagulable conditions or hematologic 
disorders. Stroke of undetermined etiology has either no probable etiology or more than one 
potential cause.  
 
Identification of the underlying cause of stroke is important since etiological information may 
influence both acute treatment and secondary preventive strategies. The TOAST classification 
is based on clinical and radiological findings as well as supplementary investigations such as 
colour duplex of precerebral arteries, ECG, echocardiography and blood samples. The 
TOAST classification has been found to be valid and reliable (61). However, the TOAST 
classification is under debate (62) since most etiological diagnoses are based on presumptions 
and not on a pathological confirmation. When MRI techniques are more available, cortical 
involvement are found in patients with clinical lacunar syndromes and vice versa. In addition, 
this full assessment for classification requires extensive investigations. Further, the use of 
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undetermined cause in a clinical setting may be difficult when there is evidence for two 
possible etiological mechanisms even if one is the most probable. In order to reduce the 
proportion of patients classified as undetermined cause, other classification systems have been 
introduced. Causative Classification System (CCS) and ASCO (A for atherosclerosis, S for 
small vessel disease, C for cardiac source, O for other cause), have shown good agreement 
with the TOAST classification, but have not been applied in larger stroke studies (63).  
 
Some colleagues differentiate between major and minor stroke. These concepts are related to 
the degree of dependency, where patients with minor stroke are in no need for assistance in 
personal activities of daily living (P-ADL), while patients with major stroke are dependent in 
activities regarding daily living.  
 
2.1.6 Classification of neurological and functional impairments in stroke 
Neurological impairments can be assessed using the NIHSS (64). Neurological deficits 
include assessment of consciousness and orientation, motor deficits, language, impaired 
coordination, inattention deficits, homonymous hemianopia and sensibility. NIHSS is used by 
stroke physicians for evaluation of size and topographic location in the acute phase, for 
decision making regarding acute therapy, for evaluation of the therapy, for predicting 
prognosis and as a measure of neurological handicap. In our stroke unit, NIHSS is also used 
by trained nurses to monitor the neurological impairments in the acute phase. NIHSS can be 
used in clinical trials to predict outcome (65).  
 
Functional disabilities are often measured using the Barthel Activities of Daily Living index 
(Barthel ADL index) (66). This scale includes impairments involving eating, personal 
hygiene, bowel-and bladder control, moving and walking. The index may be helpful when 
plans are made for further rehabilitation and need for care and assistance after discharge from 
the stroke unit.  
 
The modified Rankin scale (mRs) (66) is regarded as a global stroke scale scoring patients’ 
daily functioning from 0 (no symptoms) to 5 (severe disability, bedridden, in need of constant 
care) or 6 (death). mRs is widely used to assess global outcome after stroke in various stroke 
studies (67).   
 
2.1.7 Risk factors for stroke 
The term “risk factor” was raised based on results from the Framingham study, initiated in 
1949 to seek out a single cause sufficient to produce cardiovascular disease. Age is the most 
powerful risk factor for stroke (68). The probability of stroke in an individual depends on the 
presence and level of risk factors (69). The risk associated with each factor varies widely 
depending on the burden of associated risk factors (68). Further, the increase in risk usually 
starts from the age 55-64 (70). 
 
The key vascular risk factors for stroke  are hypertension, atrial fibrillation and diabetes 
mellitus, anthropometrical measurements (waist and hip circumference, height and weight), 
physical activity, diet and alcohol intake, smoking status, and psychosocial factors (stress and 
depression) (71;72). Persons with a normal BP (<120/80 mm Hg) have approximately half the 
lifetime risk of stroke compared with those with high BP (≥140/90 mm Hg) (73). For 
ischemic stroke, 60-80% can be attributed to increased blood pressure, increased blood 
cholesterol, cigarette smoking, carotid stenosis and diabetes mellitus (atherosclerotic ischemic 
stroke) and AF and valvular heart disease (cardiogenic ischemic stroke) (72). 
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Based on the INTERSTROKE study (71), the risk for stroke compared to persons without 
stroke and the independent contribution of each risk factor to the burden of stroke is listed 
below (Table 2). Population-attributable risk (PAR) is the risk of stroke in a total population 
that can be attributed to exposure to a specific risk factor.  
 
Table 2. Risk factors for stroke 
 
Risk factor OR CI PAR % CI 
Hypertension 2.64 2.26-3-08 34.6 30.4-39.1 
Current smoking 2.09 1.75-2.51 18.9 15.3-23.1 
Waist-to-hip ratio* 1.65 1.36-1.99 26.5 18.8-36.0 
Diet* 1.35 1.11-1.64 18.8 11.2-29.7 
Physical activity 0.69 0.53-0.90 28.5 14.5-48.5 
Diabetes mellitus 1.36 1.10-1.68 5.0 2.6-9.5 
Alcohol intake** 1.51 1.18-1.92 3.8 0.9-14.4 
Stress  1.30 1.06-1.60 4.6 2.1-9.6 
Depression  1.35 1.10-1.66 5.2 2.7-9.8 
Cardiac causes 2.38 1.77-3.20 6.7 4.8-9.1 
Apolipoproteins 
B/A1* 
1.89 1.49-2.40 24.9 15.7-37.1 
*highest vs lowest tertile 
**more than 30 drinks per month or binge drinking 
OR=Odds Ratio; CI= Confidence interval; PAR=population-attributable risk; 
Hypertension=self-reported history of hypertension or the composite of self-reported 
hypertension or blood pressure ≥160/90 mm Hg; Current smoking= any tobacco use the last 
12 months; Physical activity=moderate exercise (walking, cycling or gardening) or strenuous 
exercise (jogging, football and vigorous swimming) for 4 hours or more per week; stress= 
general stress at home and in the workplace (permanent or several periods of stress vs no or 
some periods of stress in the past year); Depression= feeling sad, blue or depressed for two or 
more consecutive weeks during the past 12 months; cardiac causes= atrial fibrillation or 
flutter, previous myocardial infarction, rheumatic valve disease or prosthetic heart valve 
 
Reynolds et al (74) suggested a J-shaped association of alcohol and all strokes. The diet risk 
score was based on foods that are associated with an increased or reduced risk of stroke. This 
score was based on findings in the INTERHEART study. They identified three major dietary 
patterns: Oriental (high intake of tofu and soya and other sauces), Western (high in fried 
foods, salty snacks, eggs and meat) and Prudent (high in fruit and vegetables) (75), where 
higher levels of the prudent pattern were protective against acute myocardial infarction. The 
dominant components in the Mediterranean diet, associated with a reduction in total mortality 
and cardiovascular risk, are moderate consumption of ethanol, low consumption of meat and 
meat products and high consumption of vegetables, fruits and nuts, olive oil and legumes 
(76;77).  
 
Regarding physical activity, 15 min a day or 90 min a week of moderate-intensity exercise 
might be of benefit, even for individuals at risk of cardiovascular disease (78). Physical 
activity is also associated with reduced risk of stroke (79). Cigarette smokers have an excess 
risk of stroke, RR 1.5 (95% CI 1.4-1.6) (80), and the risk of stroke declines considerably and 
rapidly after smoking cessation (81). Elevated body mass index (BMI) is a risk factor for 
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ischemic stroke (82). Abdominal obesity is an independent risk factor for ischemic stroke 
(83;84), stronger than BMI and with a greater effect among younger persons. 
 
Based on the findings from the INTERSTROKE study, targeted intervention for primary 
prevention should include reducing blood pressure, hyperlipidaemia and smoking, 
appropriately treatment of diabetes, promote physical activity, obesity and weight reduction 
and a healthy diet. 
 
Guidelines regarding primary prevention are listed in Table 4. 
 
2.1.8 Secondary prevention after stroke 
Antiplatelet therapy is protective in most types of patients at increased risk of occlusive 
vascular events (85). Addition of modified-release dipyridamole to aspirin leads to a relative 
risk reduction of all major vascular events of 22% (86). The combination of aspirin and 
dipyridamole was recommended as antithrombotic therapy after cerebral ischemia of arterial 
origin (87). Long-term administration of clopidogrel to patients with atherosclerotic vascular 
disease was more effective than aspirin in reducing the risk of ischemic stroke, myocardial 
infarction or vascular death (88). The PRoFESS study (89) showed similar rates of recurrent 
stroke with aspirin and dipyridamole versus clopidogrel. The combination of aspirin and 
clopidogrel did not reduce the risk of stroke, MI, vascular death or re-hospitalization, 
compared to clopidogrel alone, however, life-threatening or major bleeding increased (90). 
However, the choice of antiplatelet regime is contentious (91), and the recent guidelines (92) 
no longer specify the antiplatelet regime. 
 
Anticoagulant therapy is superior to antiplatelet therapy for the prevention of stroke in people 
with non-rheumatic artial fibrillation with or without a history of stroke or TIA (55;56). 
Warfarin and antiplatelet agents reduce stroke by approximately 60% and 20 % respectively 
in patients with atrial fibrillation (93). Different risk stratification schemes have been 
developed. Patients with low risk for developing stroke according to the CHADS2 score 
(congestive heart failure, hypertension, age, diabetes mellitus and prior stroke or TIA) 
(94)(Table 3) or who have contraindications against oral anticoagulation with vitamin K 
antagonists, should be treated with aspirin (95). CHA(2)DS(2)-VASc adds risk factors-age 
65-74 years, presence of vascular disease and female sex, and gives two points for age 75 
years or older, identifying those with a truly low risk but more with high risk (96). Since both 
risk of stroke and incidence of AF increase with age, stroke prevention in the elderly is 
important. Age alone is not regarded as a contraindication for anticoagulation (94). 
 
Table 3. CHADS2 score 
 
Risk factor Points allocated 
Prior stroke or TIA 2 
Age >75 years 1 
Hypertension 1 
Diabetes mellitus 1 
Heart failure 1 
 
Weimar, expert reviews 2009 (94). 
 
Dabigatran, an oral reversible direct thrombin inhibitor, reduces stroke in patients with AF 
and previous cerebrovascular events (97). 150 mg twice daily was superior to warfarin while 
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110 mg twice daily was non-inferior. Rivaroxaban is an alternative to warfarin for prevention 
of initial and recurrent stroke in patients with AF (98).  
 
The Framingham study showed that a risk factor seldom occurs alone, and the risk associated 
with each varies widely depending on the burden of associated risk factors (68). Aggressive 
control of the individuals’ risk factors requires multivariable risk assessment. Further, the 
Framingham study showed that the average number of risk factors increased with the patients’ 
weight (68). Treatment of high blood pressure (99) is associated with reduced stroke 
recurrence after stroke or TIA. An absolute target blood pressure level and reduction is 
uncertain, and should be individualized, but benefit has been associated with an average 
reduction of almost 10/5 mm Hg, and normal blood pressure levels have been defined as 
<120/80 mm Hg (92;100). Lifestyle modifications should be included as part of a 
comprehensive antihypertensive therapy (92). Treatment of hypertension in the acute phase 
does not affect outcome positively (101). 
 
In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial 
(102), statin therapy with high dose of atorvastatin reduces stroke recurrence (HR 0.84; 95% 
CI 0.71-0.99). 96% reached ≥50% decrease in LDL. In the Heart Protection Study (HPS) 
(103), simvastatin reduced vascular events in patients with prior stroke, and reduced stroke in 
patients with other vascular disease (RR 0.76). Management of elevated cholesterol includes, 
in addition to statin agents, lifestyle modifications and dietary guidelines (100). There is good 
evidence that lowering blood cholesterol with statins reduces stroke risk and carotid 
atherosclerosis, independently of blood cholesterol, blood pressure and age (104).  
 
Regarding cigarette smoking, diet and overweight, there are no specific data regarding 
secondary prevention. However, there is evidence for recommending smoking cessation. 
Further, there is consensus regarding reduction of heavy consumption of alcohol. In the 
AHA/ASA guidelines, light to moderate levels of no more than two drinks per day for men 
and one drink per day for non-pregnant women may be considered (92;100). Weight 
reduction may be considered for all overweight patients with ischemic stroke and TIA to 
maintain the goal of BMI between 18.5 and 24.9 kg/m2 and waist circumference of <88 cm in 
women and <102 cm in men. However, low BMI is an independent risk factor of total 
mortality in the elderly (105), and a reduction of BMI up to 28 kg/m2 may not be beneficial in 
older adults. Clinicians should encourage weight management through an appropriate balance 
of calorie intake, physical activity and behavioral counseling (100). Regarding diet, the 
general recommendation from 2006 was to balance calorie intake and physical activity to 
achieve or maintain a healthy body weight. Further, we should encourage consuming a diet 
rich in vegetables and fruit, high-fiber foods, oily fish at least twice a week, minimize 
beverages and foods added with sugar, prepare foods with little or no salt and limit the intake 
of saturated fat (106).  
 
For patients capable of engaging in physical activity, at least 30 minutes of moderate-intensity 
physical activity most days is now recommended (100). Earlier recommendations were 30-60 
minutes 3-4 days a week (107) and 20-60 minutes 3-7 days a week (108). A supervised 
therapeutic exercise regime is recommended for individuals with disabilities (100). 
Rehabilitation programs are designed to optimize functional motor performance in stroke 
survivors and to improve muscle strength and cardio-respiratory fitness (108). The range of 
the approach varies from remedial gait retraining in hemiparetic stroke patients to supervised 
or home-based walking, running or strength training.  
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Increased homocysteine is associated with increased risk of ischemic stroke (109). In 2006, 
there was insufficient evidence to confirm that homocysteine was a modifiable risk factor for 
stroke (110;111), but recommended based on a meta-analysis (112). However, daily 
administration of folic acid, vitamin B6 and vitamin B12 to patients with recent stroke or TIA 
was safe but did not reduce the incidence of major vascular events (113). These results did not 
support the use of B vitamins to prevent recurrent stroke.    
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Table 4. Risk factor management regarding primary and secondary stroke prevention 
 
Risk factor Secondary 
prevention* 
Secondary 
prevention** 
Secondary 
prevention*** 
Secondary 
prevention**** 
Secondary 
prevention***** 
Primary 
prevention** 
Primary 
prevention**** 
Hyper-
tension 
BT <140/90 Blood 
pressure 
should be 
lowered, 
irrespective of 
its level 
Should be 
individualized, 
but benefit has 
been associated 
with an average 
reduction of 
almost 10/5 
mm Hg 
Blood pressure 
lowering is 
recommended, 
target BP should 
be 
individualized, 
normal BP is 
defined as 
<120/80 
BP reduction is 
recommended, 
and should be 
individualized. 
Benefit is 
associated with a 
reduction of 
approximately 
10/5 mm Hg 
<140/90 
(<135/85 in 
diabetes) 
Aiming normal 
levels of 120/80 
mm Hg 
(<130/80 in 
diabetes) 
Should be 
lowered to 
140/85 mm Hg 
or below 
Current 
smoking 
Cessation All smokers 
should stop 
smoking, 
especially 
patients who 
have had 
stroke 
Advise to quit Discouraged Strongly advise 
the patients to 
quit 
Discouraged Discouraged 
Body mass 
index 
≤120% of 
ideal body 
weight for 
height 
 Maintain BMI 
18.5-24.9 
Subjects with an 
elevated body 
mass index are 
recommended to 
adopt a weight-
reducing diet 
 Subjects with 
an elevated 
body mass 
index should 
take a weight-
reducing diet 
Subjects with an 
elevated body 
mass index (≥25) 
should take a 
weight-reducing 
diet 
Diet    A low salt, low 
saturated fat, 
high fruit and 
vegetable diet 
rich in fiber is 
recommended 
 A low salt, 
low saturated 
fat, high fruit 
and vegetable 
diet rich in 
fibre is 
recommended 
A diet  low in 
salt and 
saturated fat, 
high in fruit and 
vegetable and 
rich in fibre is 
recommended 
Physical 
activity 
30-60 
minutes of 
activity at 
least 3-4 
times/week 
 At least 30 min 
of moderat-
intensity 
physical 
exercise most 
days 
Regular physical 
activity is 
recommended 
At least 30 min of 
moderate-
intensity physical 
exercise 1 to 3 
times a week 
Regular 
physical 
activity is 
recommended 
Regular physical 
activity is 
recommended 
2-5 hour per 
week 
Diabetes 
mellitus 
Glu<6.99  More rigorous 
control of 
blood pressure 
and lipids. 
Glucose 
control. 
HBA1c ≤7  
 Use existing 
guidelines for 
glycemic control 
and BP targets 
Control of 
glucose level 
due to benefits 
of other 
diabetic 
complications  
Individualized 
pharmacological 
therapy. When 
diabetes: BT 
below 130/80 
Alcohol 
intake 
Moderat 
consumtion 
(≤2 drinks/d) 
 Heavy drinkers 
should reduce 
consumption. 
Heavy use 
should be 
discouraged 
Heavy drinkers 
should eliminate 
or reduce their 
consuption 
Heavy use 
should be 
discouraged 
Heavy use 
should be 
discouraged 
Hyper-
lipidaemia 
LDL<2.6 Statin therapy 
should be 
considered 
Target 
LDL<2,6 
Statin therapy is 
recommended in 
subjects with 
non-cardio-
embolic stroke 
Statin therapy is 
recommended 
when evidence of 
atherosclerosis 
and LDL >2.5. 
Target: 50% 
reduction of LDL 
or LDL <1.8 
Simvastatin in 
high-risk 
patients 
If  LDL >3.9 
mmol/l, lifestyle 
intervention and 
a statin 
Hormone 
replacement 
therapy 
 Not 
recomended 
 Not 
recommended 
Not 
recommended 
Should not be 
used 
Not 
recommended 
* Preventing Ischemic Stroke in Patients With Prior Stroke and TIA, AHA, Stroke 1999 (107) 
**European Stroke Initiative Recommendations for Stroke Management-Update 2003 (114) 
*** Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient 
Ischemic Attack, AHA/ASA Guidelines 2006 (100) 
**** Guidelines for management of Ischaemic Stroke and Transient Ischaemic Attack 2008 
(22) 
*****Guidelines for the Prevention Of Stroke In Patients With Stroke or Transient Ischemic 
Attack, AHA/ASA Guidelines 2011 (92) 
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Hormone replacement therapy, estrogen with or without progestin, was frequently used to 
treat symptoms of menopause and to prevent osteoporosis and cardiovascular disease. 
However, use is associated with increased risk of ischemic stroke (115) and not recommended 
after stroke (92).  
 
Traditionally, there is a gap between recommended secondary prevention and observed 
practice (116). Secondary prevention treatment declines rapidly during the first two years 
after stroke (117), and almost one-third of patients with stroke discontinue secondary 
prevention within the first year of hospital discharge (118). There is lack of effective 
interventions to improve persistent adherence to treatment post-stroke (117). 
 
2.1.9 Cognitive impairments after stroke 
Cognitive impairments after stroke include focal dysfunctions from the stroke lesion and more 
global dysfunction probably related to hypoperfusion and underlying vascular and 
degenerative pathology (119).  
 
The most well-known and classical cognitive deficit occurring in acute stroke is aphasia 
which affects approximately 15-25% of all stroke patients (120;121). Cortical lesions in the 
dominant hemisphere (left side in most cases) may lead to aphasia (language impairment), 
apraxia (loss of ability to perform learned tasks) and agnosia (loss of ability to recognize 
objects), while cortical lesions in the right hemisphere frequently may cause inattention 
phenomena and neglect (failure to attend or respond to stimuli on the side contralateral to the 
stroke), visuospatial impairments (the ability to understand visual representations and their 
spatial relationships) and reduced insight in one’s own situation.  
 
Global cognitive deficits post-stroke include impaired memory, impaired concentration, 
reduced psychomotor speed and attention, reduced executive functioning and general fatigue 
(122). Executive function involves the ability to sequence, plan, organize, initiate and shift 
between tasks. The characteristic cognitive profile of subcortical ischemic vascular disease 
includes early impairment of attention and executive function, with slowing of motor 
performance and information processing. Additional impairments of global cognition may be 
associated with worse functional outcomes (123). 
 
Post-stroke dementia is defined as any dementia occurring after stroke, and includes VaD, 
degenerative dementia (mostly AD) and mixed dementia (coexistence of vascular and 
degenerative changes). Vascular and degenerative changes seem to interact and coexist in 
post-stroke dementia, resulting in cumulative brain damage and cognitive decline (12;124). 
Post-stroke cognitive impairments include the continuum from subjective and mild cognitive 
impairment to manifest dementia. The prevalence of post-stroke dementia is increasing, 
probably mainly due to the decline in stroke mortality and the increasing life expectancy in 
the population. Suffering a stroke doubles the risk of dementia (125). Previous studies have 
reported different rates of post-stroke dementia; the prevalence estimated one year after stroke 
varies between 7.4 % in population-based studies of first-ever stroke, when patients with pre-
stroke dementia are excluded, to 41.3 % in hospital-based cohorts including recurrent stroke 
and pre-stroke dementia (126). Rates of post-stroke cognitive impairment differ even more, 
from 11.6 to 56.3 % (8), depending on the population under study, criteria for cognitive 
impairment, and the time-interval between stroke and testing. 
 
In 2007, the hypothesis regarding prevention of cognitive symptoms after stroke by intensive 
vascular risk factor intervention was based mainly on logical assumptions: VaD and AD share 
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the same vascular risk factors and there is an increased risk of dementia after stroke. In 
addition, active treatment of blood pressure was related to reduced risk of dementia and 
cognitive decline associated with recurrent stroke, supporting the recommendation of blood 
pressure therapy post-stroke (127).  
 
Today, there is still little evidence for effect of vascular risk factor control and prevention of 
post-stroke cognitive impairment. Few studies include cognitive outcome measures as 
primary endpoints. However, despite limited evidence, management of vascular risk and 
lifestyle factors are recommended post-stroke (128). Better pre- and post-stroke control of 
vascular risk factors and improved stroke care may contribute to preserving cognitive 
functioning after stroke (129).  
 
Vascular risk factors contribute not only to vascular dementia, but most probably also in the 
cascade of Alzheimer pathology proceeding to clinical dementia (11). In patients with 
neuropathological signs of AD, the presence of vascular lesions seems to accelerate the debut 
of clinical symptoms (130), and the presence of one or two apolipoprotein E (Apo E) 4 alleles 
is found to be a risk factor for cognitive impairment after stroke (131).  
 
2.1.10 Assessments of cognitive impairments after stroke 
Cognitive assessment in the acute phase is complicated due to lack of standardized assessment 
tools for testing post-stroke and less knowledge regarding pre-stroke cognitive function. In 
addition, the patients may be influenced by medical factors (ie, previous stroke, aphasia, 
neglect, fever, medication, delirium). The use of cognitive assessments in the acute phase of 
stroke cannot be used for the diagnosis of dementia or the diagnosis of Mild Cognitive 
impairment (MCI), but for detection of cognitive deficits and to evaluate whether there is a 
need for rehabilitation, assistance to support performance of activities of daily living and for 
follow-up.  
 
Patients suffering from stroke may have specific cognitive deficits (ie, aphasia or neglect) as 
well as more global cognitive dysfunction. Cognitive assessments should evaluate different 
cognitive domains, including testing for language, neglect, praxis and more global cognitive 
function including memory, motor speed, executive function and attention. Screening tools 
should be sensitive enough to detect all those with symptoms and specific, in order to identify 
symptoms only if present. Further, the test should be quick and easy to administer and the 
patients must be able to tolerate the assessments.  
 
The Mini Mental State Examination (MMSE) (132) is widely used for global cognitive 
screening, but may not be so useful in detection of cognitive impairments after stroke due to 
lack of sensitivity (133). The standard cognitive measures tend to underestimate executive 
dysfunction and effects of cognitive dysfunction on global and daily function. The 
coexistence with physical deficits may also complicate the assessment.  
 
In the present study we included the following instruments to assess the different domains:. 
 The MMSE (standard, 30-point). MMSE is considered as a screening for 
global cognitive functioning, and evaluates orientation, concentration, 
language, praxis and memory. The test does not include a measure of executive 
functioning. 
 The Clock Drawing Test (CDT) (134;135). This is primarily a measure for 
visuospatial functions. 
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 The Trail Making Test A and B (TMT A and B) (136). The TMT A is a 
measure of focused visual attention and information processing, while TMT B 
measures executive functioning in which participants connect a series of 
alternating numbers and letters. TMT A is a predictor for cognitive ability 
post-stroke (137). 
 The 10 word test (max score 40) including delayed recall from the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS) (138). This 
is a measure of memory impairment. It is a test of verbal episodic memory 
with immediate and delayed recall scores. 
 Figure drawings from Alzheimer's Disease Assessment Scale-cognitive 
subscale (ADAS-cog) (139). The ADAS-cog was designed to evaluate both 
cognitive and non-cognitive behavioural dysfunctions in patients with AD. The 
figure drawings tests visuoconstruction. 
 Ullevaal Aphasia Screening (UAS) (140) is used for aphasia screening, a 
simple test for nurses identifying language disability. 
 
Unfortunately, pre-stroke cognition is impossible to measure post-stroke. Retrospective (post-
stroke) assessment of pre-stroke cognition can be done with the Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE) (141), which was used in the present study. The 
ICCODE is applied to measure a possible cognitive reduction over the last 10 years preceding 
the stroke, and is based on an interview with a family member or carer who knows the patient 
well. The IQCODE is a measure of general cognitive decline, and is relatively unaffected by 
education and pre morbid intellectual ability (142). 
 
2.1.11 Prognosis after stroke 
In 1997 a Norwegian study reported that about 19% of patients with acute stroke died within 
30 days, 10,9% due to cerebral infarction (18). Twelve years later, thirty-day mortality by 
ischemic stroke is reduced to 2.8% in Norway in 2009 (6). Two-thirds of the decreasing 
mortality in the past decades are attributable to reduced case fatality, and one third to reduced 
attack rate (143). The first is related to treatment, the latter to prevention (4). 
 
One-year survivors of first-ever stroke continue to die over the next 4 years at a rate of 
approximately 10% per year (144). The 1-year mortality for patients with TACI is higher 
(about 60%) than PACI and POCI (about 15-20%), which in turn is higher than patients with 
LACI (10%) (145). The most common cause of death is cardiovascular disease (145)(same 
ref). In Norway, the 12-year mortality rate was 86.5% (146), associated with age, male sex, 
stroke severity, ischemic heart disease, diabetes and hemorrhagic stroke. A significantly 
higher case-fatality rate was observed among recurrent stroke and with increasing age (143). 
 
In addition to mortality, disability represents the most relevant negative clinical outcome. 
Stroke is, after AD and other dementia related neurological disorders, the main cause of long-
term neurological disability in adults with up to one-third of survivors being left dependent on 
others for everyday activities (5). The best predictors of stroke recovery at 3 months are the 
initial neurological deficits and age (147). Other factors influencing the outcome include high 
blood glucose concentrations, urinary incontinence (148), body temperature, previous stroke 
and right and left arm weakness together with the mRS score 48 to 72 hours (147). Female 
gender was found to be a predictor for functional independence, but not mortality. 
Neurological complications, including recurrent stroke, parenchymal hemorrhage and 
epileptic seizures were associated with impaired function. Compared to other stroke types, 
lacunar strokes have better prognosis including almost no acute mortality and a general good 
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short-time recovery. However, in the long term there is an excess risk of death, recurrent 
stroke and development of cognitive dysfunctions.   
 
When we consider prognosis, we have to include the risk of developing cognitive impairment, 
dementia and other behavioral dysfunctions including asymptomatic progression of small-
vessel disease. Cognitive impairments after stroke have received growing attention in the past 
decade. Lacunar infarcts are regarded as a marker of cerebral small vessel disease with 
increased risk of disability, cognitive impairment and dementia (59).  
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2.2 Dementia and Mild Cognitive Impairment (MCI) 
Dementia is from the Latin term demens, from de- "without” and -mens "mind". Dementia is 
defined as a chronic condition due to diseases in the brain characterized with cognitive 
impairment, impairment in activities of daily living and with affection of behavior or 
personality. Dementia may not be considered as a disease, but as a syndrome. According to 
International Classification of Diseases (ICD-10) (149) and Diagnostic and Statistical Manual 
of Mental Disorders (Fourth Edition) (DSM-IV) (150) criteria the syndrome is defined in 
different ways, but most people with dementia are captured by both definitions (151). 
 
2.2.1 The cognitive impairment in dementia 
The cognitive impairment involves memory, attention, language, problem solving, executive 
functions and the general processing of information. The symptoms influence the patients’ 
performance in the ADL and to some degree the patient’s behavior. The symptoms have to be 
persistent for six months to obtain a confident clinical diagnosis according to the ICD-10 
criteria. 
2.2.2 Mild Cognitive Impairment (MCI)                                                                            
MCI is considered a transitional state between the cognitive changes of normal aging and 
dementia. Many definitions exist, but the one most used is that of the Mayo clinic (152). The 
degree of cognitive impairment does not influence on the ADL function. When these persons 
are observed longitudinally, about half of them progress to clinically dementia within five 
years (153;154). Consequently, this condition has been recognized as suitable for possible 
therapeutic intervention. 
Figure 3. Theoretical progression of a person developing Alzheimer's disease (AD) 
 
 
Petersen, R. C. (153). 
 
 
2.2.3 Prevalence of dementia 
Dementia affects more than 60.000 persons (probably 70 000) in Norway (7;155). The 
prevalence increases with increasing age, and affects around 15% at age 75 and higher. Every 
year, 9000 persons in Norway are diagnosed with dementia, most often of degenerative 
origin, but also of vascular and mixed etiology. Late-life AD debuts after the age of 65, the 
early form before. 
 
The prevalence of all-cause dementia almost doubles every 5 years of age (156), and the 
prevalence of dementia and AD rise linearly with an increase exponentially with age.  
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2.2.4 Etiology of dementia 
In younger patients with dementia, one etiology may dominate. In the elderly, the etiology is 
often mixed with coexistence of vascular and degenerative components.  
 
Dementia can be due to neurodegenerative disorders like AD (60%) (157;158), fronto-
temporal dementia (FTD) (5%), Lewy-Body disease and Parkinson’s disease (15%) or 
cerebrovascular changes (vascular dementia (20%) and dementia in association with traumas, 
tumors and endocrine, infectious or autoimmune diseases (159-161). In younger persons, 40% 
suffer from pure AD and 20-30% from FTD. The hallmark lesions of AD are Aβ plaques 
(amyloid accumulation) and neurofibrillary tangles (marker of neuronal injury) formed by 
abnormal tau (162).  
 
Cognitive impairments associated with cerebrovascular disease extend beyond the traditional 
concept of multi-infarct dementia, and refer to cognitive decline due to vascular disease (161).  
 
2.2.5 Diagnosis of dementia 
The diagnostic assessments of dementia start with a careful anamnesis from the patient and 
the spouse or close relative/friend, a clinical examination, cognitive assessments and a 
physical examination, including blood tests. 
 
Examination of biomarkers in cerebrospinal fluid and advanced brain imaging techniques 
facilitate a more precise etiological diagnosis (differential diagnosis) of a given type of 
dementia.  
 
The diagnosis is based on different criteria such as the DSM-IV and the ICD-10. The DSM-
IV criteria include changes in personality, whereas the ICD-10 includes changes in behavior. 
 
Table 5. Dementia according to the ICD-10 criteria for research 
 
A. Evidence of each of the following 
1. Decline in memory (mainly episodic memory)  
2. Decline in other cognitive abilities (at least one) 
 
Deficits in criterion A cause a significant impairment of social functioning 
B. Absence or clouding of consciousness 
C. Decline in emotional control or motivation or a change in social 
behavior  
 
 
D. Symptoms in criterion A have been present ≥6 month 
 
2.2.6 Diagnosis of MCI 
Individuals with cognitive impairments but preserved performance in activities of daily living 
who do not meet the criteria for overt dementia are referred as patients with MCI (152;153). 
According to the criteria, besides subjective memory impairment, preserved general 
intellectual function, intact ADL and absence of overt dementia, objective memory 
impairment must be present to meet the diagnostic criteria for MCI. Another set of criteria is 
made by Winblads et al (163) that include patients with deficits in different cognitive 
domains.  
 
Impairment in episodic memory, atrophy on MRI and AD biomarkers in spinal fluid can be 
used to predict the likelihood of progression to dementia (164), affecting 40-60% of patients 
with MCI (154). The use of biomarkers for prediction is under debate (165), and clinical 
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criteria without use of biomarkers persist (166). Some patients with subjective cognitive 
impairment may also develop AD, but after longer follow-up time (167). 
 
2.2.7 Diagnosis dementia due to Alzheimer’s disease 
The clinical characteristic for AD is an insidious onset and a gradual decline in cognitive 
function. For the majority of patients, the initial symptom is impairment in episodic memory, 
affecting the ability to learn and retain new information. This is followed by impairments in 
other cognitive domains including executive function, language and spatial ability.  
 
A diagnosis of dementia due to Alzheimer’s disease is made in ICD-10 (Table 6). 
  
Table 6. Alzheimer’s disease according to the ICD-10 criteria 
 
1. Evidence of dementia according to the ICD-10 criteria 
2. Evidence of no other organic brain disorder or drug induces affection  
 
It also differentiates between early onset and late onset AD. Below the age of 65, the start or 
progression is fast or the cortical deficits are multiple. In AD with debut in older age, the start 
and progression is slower and the memory impairment is dominating.     
 
A diagnosis of dementia due to Alzheimer’s disease based on the DSM-IV criteria is the 
development of multiple cognitive deficits that include memory impairments and impairment 
in at least one other cognitive domain that is a decline from the previous level of functioning 
and is sufficiently severe to cause impairment in function. 
 
A diagnosis of AD can also be made according to the National Institute of Neurological 
Disorders and Stroke criteria (NINCSDS-ADRDA) (157). These clinical criteria include 
insidious onset and progressive impairment of memory and other cognitive functions. These 
criteria were revised in 2011 (158). The core clinical criteria for AD dementia are the 
cornerstone of the diagnosis in clinical practice.  
 
The most frequently used CSF biomarkers are beta-amyloid peptide, total tau-protien (T-tau) 
and phosphorylated tau (P-tau) (168). There is an inverse correlation between CSF levels of 
beta-amyloid and brain amyloid deposition (169). Elevated T-tau and P-tau are probable 
markers for axonal damage and tangle formation (170). For discrimination of AD from non-
AD the sensitivity of all the CSF biomarkers are 80% and the specificity 93% (171). 
 
New research criteria for the AD diagnosis have been proposed by experts (172) and include, 
in addition to memory impairment, at least one positive biomarker (MRI/PET/CFS markers). 
Brain images are recommended because they can improve diagnostic accuracy (173). Much 
work lies ahead for validating the biomarker diagnosis of AD dementia, and the new proposed 
criteria for use in research. 
 
2.2.8 Diagnosis of vascular dementia 
VaD is a heterogeneous clinical condition based on various vascular pathological processes 
underlying the subtypes of cerebrovascular disease. This includes lacunar infarction, cortical 
infarction, subcortical infarction, white matter lesions, cardiogenic emboli, hypotensive 
infarction, intracerebral hemorrhages, lobal hemorrhages and subarachnoid hemorrhage.  
The criteria for VaD include the criteria for the dementia syndrome that should be caused by a 
vascular disorder. The most used criteria are those in ICD-10 (Table 7), DSM-IV and 
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National Institute of Neurological Disorders and Stroke-Association Internationale pour la 
Recherche et l'Enseignement en Neurosciences (NINDS-AIREN), none of which are ideal 
(174). ICD-10 and NINDS-AIREN require focal neurological signs, ICD-10 and DSM-IV do 
not include neuroimaging and ICD-10 has a requirement of unequal distribution of higher 
cognitive functions. In the DSM-V, expected in 2013, the new concept “neurocognitive 
disorders” will be introduced, dividinginto major and minor depending on whether ADL are 
affected or not, and includes the underlying cause for the cognitive impairment. 
 
Table 7. Vacular dementia (VaD) according to the ICD-10 criteria 
 
A Dementia according to theICD-10 criteria 
B Deficits in higher cognitive functions are unequally disturbed 
C Clinical evidence of focal brain damage 
D Evidence from history, examination or tests of a significant 
cerebrovascular disease (eg. a history of stroke, evidence of 
cerebral infarction) 
 
 
2.2.9 Diagnosis of vascular cognitive impairment 
The concept of vascular cognitive impairment (VCI) has been introduced to capture the entire 
spectrum of cognitive disorders associated with cerebrovascular disease (161). VCI refers to 
the total vascular burden on the brain, and the effect of vascular disease or lesions on 
cognition. Vascular disease includes both the cerebrovascular event and small vessel disease 
without stroke (ie, silent lacunar infarcts, ischemic white matter lesions and incomplete 
ischemic injuries).VCI refers to cognitive impairments due to cerebral vascular disease not 
fulfilled by traditional criteria for dementia.  
 
2.2.10 Neuroimaging 
Cerebral MRI is used to identify a core area of the stroke lesion which is often associated with 
impairment of a corresponding cognitive function. In addition, imaging can identify 
subclinical injury including cerebrovascular disease and regional and global atrophy. Since all 
these factors are thought to act synergistically in the development of cognitive dysfunction 
after stroke, evaluation of cerebral MRI should be included in post-stroke cognitive 
assessments.   
 
Measurements of cerebral white matter lesions (WML), white matter hyperintensities (WMH) 
or white matter changes (WMC) changes from CT and MRI can be done using scores to 
quantify white matter lesions (175-178), or semi-automated methods (179;180). White matter 
lesions present as diffuse low-density areas on CT scans and as areas of hyperintensity on T2-
and FLAIR-weighted MRI scans. These white matter lesions/hyperintensities/changes, 
initially described in 1987 and named leuko-araiosis (181), are related to variable degrees of 
demyelination, axonal loss and gliosis (182). 
 
Cerebral atrophy can be measured according to the method first described by Scheltens et al 
(183). Based on the height of the hippocampal formation and enlargement of the surrounding 
cerebrospinal fluid spaces, the medial temporal lobe atrophy (MTLA) is graded from 0 to 4. 
MTLA grade 0=no atrophy; MTLA 4=highest degree of atrophy. MTLA 0-1 is considered a 
normal value. Other methods, including volume measures, are available.  
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2.2.11 Risk factors of dementia  
The strongest risk factor for dementia is increasing age (184), followed by having the ApoE 
ɛ4 allele (185), midlife hypertension and high cholesterol (186) and head injury (187). Other 
vascular risk factors, such as high midlife waist-to-hip ratio (188), smoking (189), slow 
physical performance (184), diabetes (190;191) and elevated homocysteine (192), also 
represent a risk for late-life dementia. Stroke and vascular risk factors increase the risk of both 
AD and VaD. 
 
Hypertension is a risk for general atherosclerosis including stroke and cardiovascular disease.  
There is reported an association between high blood pressure and later development of 
dementia, both AD (193) and VaD (194). In AD, blood pressure is increased 5-15 years 
before dementia onset, and then decreases in the years immediately preceding dementia onset 
(193). Blood pressure continues to decrease during the disease process. 
 
In addition, various genetic and environmental factors, including early-life brain development, 
body growth, socioeconomic conditions, environmental enrichment and cognitive reserve, are 
likely to contribute to dementia risk (195). The decreased reserve capacity of the brain include 
reduced brain size, low educational and occupational attainment, low mental ability in early 
life and reduced mental and physical activity during late life (162). However, regarding these 
factors, there is less evidence, compared to the knowledge about the vascular risk factors.  
 
Age, a low educational level and pre-stroke cognitive impairment are known risk factors for 
post-stroke dementia (126). In addition, diabetes and atrial fibrillation (AF) are significantly 
associated with post-stroke dementia. Most predictors relate to the stroke per se, i.e. stroke 
severity, stroke recurrence, left hemispheric lesion, and hemorrhagic etiology. Some of the 
most common complications of stroke are also described as risk factors, e.g. incontinence, 
epileptic seizures, hypotension and delirium (126).  
 
Small vessel disease without stroke, including silent lacunar infarcts, ischemic white matter 
lesions and incomplete ischemic injury, is a marker of poor prognosis with increased risk of 
stroke, cognitive impairment, steep decline in global cognitive function, dementia and death 
(59;128;161;196-198).  
 
2.2.12 Prevention and treatment of dementia 
There is no clear evidence that any intervention can prevent or delay the onset of dementia. 
 
In spite of this, most clinicians and researchers in the field recommend that vascular risk 
factors should be treated aggressively, not only to prevent heart disease and stroke, but to 
decrease the likelihood of cognitive impairment (and dementia) in later life (12;194). 
Aggressive control of the individual’s risk factors requires multivariable risk assessment. 
Hypertension often clusters with other vascular risk factors, including diabetes mellitus, 
obesity, homocysteine and hypercholesterolemia, all related to dementia of both degenerative 
and vascular origin. Midlife control of vascular risk factors are of importance in order to 
preserve cognitive function, in addition to building  a ”cognitive reserve” through a healthy 
lifestyle including physical activity and mental stimulation.   
 
Treatment of hypertension in the elderly shows reduction in stroke and total mortality (199), 
but does not statistically reduce the incidence of dementia (200), the latter maybe due to short 
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follow-up. One study has shown an association between antihypertensive treatment and a 
lower incidence of dementia (201).  
The strongest predictor of cognitive decline after an initial stroke is the occurrence of a 
second stroke (128). The risk rises to approximately 30%. The prevention of VaD is based on 
stroke prevention which implies risk factor manipulation and use of antithrombotic drugs.  
 
There is still no indication of any significant benefits from cognitive training in early stages of 
AD and VaD (202), but it is not possible to draw conclusions due to the lack of a- randomized 
controlled trial (RCT). Regarding diet, the Mediterranean dietary pattern may reduce the rate 
of cognitive decline with older age (203). Regular physical activity seems to protect against 
the occurrence of cognitive decline (204). 
 
Prevention and treatment of dementia due to AD includes environmental involvement and 
medical treatment in order to preserve function. There is no disease modifying treatment in 
AD. Cholinesterase inhibitors (donepezil, rivastigmin and galantamine) are effective at the 
symptom level for mild to moderate AD and memantine for moderat to severe AD (173;205). 
Cholinesterase inhibitors delay the breakdown of acetylcholine released into synaptic clefts, 
and so enhance cholinergic neurotransmission. There is no evidence of any difference 
between them with respect to efficacy (205). There is lack of evidence regarding statin, anti-
inflammatory drugs, vitamin E and Ginko.  
 
Pharmacological approaches to reduce amyliod and/or tau deposits are in progress. Several 
clinical trials with monoclonal antibodies against amyloid-β are ongoing (206), but so far no 
positive results are published.  
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3. Objectives/aims 
 
The four aims of the thesis were: 
 
The TOAST study: To evaluate the distribution of the different etiological stroke subtypes in 
a hospital-based sample of first-ever patients with stroke or TIA, and to investigate the 
association between possible risk factors and stroke subtypes.  
 
The intervention study: To investigate whether more intensive treatment of vascular risk 
factors in patients with first-ever stroke or TIA can influence post-stroke cognitive 
functioning in patients free from cognitive decline prior to the stroke. 
 
The MCI/dementia study: To assess the incidence of post-stroke dementia and MCI one year 
after stroke and TIA in a population free from pre-stroke cognitive decline. Further, we 
wanted to investigate the different etiological subtypes of post-stroke dementia and MCI, 
using a new method of sub-classification.   
 
The WML study: To evaluate the associations between WML and patients` performance at 
one year post-stroke on tests measuring executive functioning, memory and visuospatial 
function. 
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4. Methods 
4.1 Participants 
All patients with a first-ever stroke or TIA admitted to the stroke unit of Asker and Baerum 
Hospital between February 2007 and July 2008 were invited to participate in the study. Only 
those patients who survived the acute phase were assessed. The hospital has a policy of 
admitting all stroke patients directly to the stroke unit, and serves two local municipalities 
with a total population of approximately 160,000.  
 
We excluded patients with subarachnoid hemorrhage, known cognitive decline as indicated 
by a score ≥3.7 on the Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE), previous stroke or TIA, patients who did not speak Norwegian and patients with a 
life expectancy less than one year.  
 
After inviting 253 patients, 250 patients accepted to participate in the study. Of these, 23 
patients were excluded: 12 did not fill the inclusion criteria (six had an IQCODE score ≥3.7, 
one did not speak Norwegian, one had an infarct in the spinal cord, one had suffered a 
previous TIA, two withdrew their consent and one died before signing the consent) and 11 
patients were diagnosed with other disease than stroke.  
 
Of the 227 remaining patients, 174 (76.7%) had a cerebral infarction, 36 (15.9%) had suffered 
a TIA and 17 (7.5%) were diagnosed with a cerebral hemorrhage.  
 
For the TOAST study, only patients with ischemic cerebrovascular disease, i.e. infarction or 
TIA, were included in statistical analyses regarding the TOAST classification (n=209). After 
the follow-up, one patient was found to be wrongly classified. 
 
For the intervention study, only patients who were able to perform the TMT A, the 10 word 
test or both were randomized. After excluding 32 patients (24 not testable, three persons 
suffered a new stroke before randomization, two did not want randomization, one was 
diagnosed with a new subdural hematoma, one was diagnosed with advanced cancer and one 
withdrew his consent after advanced heart surgery), 195 patients were randomized to either 
the intervention group (n=98) or the control group (n=97).  
 
During the follow-up period of 12 months, eight patients discontinued and five patients died 
in the intervention group, while four died in the control group. The main reasons for 
permanent discontinuation were tiredness or unwillingness to be reminded about the stroke. 
One patient discontinued after having his driver’s license withdrawn. None dropped out of the 
intervention program due to side-effects of drugs. 85 patients in the intervention group and 93 
controls completed the follow-up.  
 
In the MCI/dementia study, we used the cut-off 3.44 to minimize the probability of including 
patients with a pre-stroke MCI, leaving 208 patients. 
 
All 227 patients were included in the WML study. 
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Figure 4. Flow chart at baseline regarding the four substudies 
 
 
 
 
 
 
209 patients were included in the TOAST study. Due to a wrong punching, 210 should have 
been included. 
 
4.2 Assessments 
4.2.1 Assessments at baseline 
The primary distinction between ischemic stroke and hemorrhagic stroke was based on 
neuroimaging with cerebral CT and MRI.  
 
Vascular risk factors recorded at baseline included treated hypertension before hospitalization, 
hyperlipidemia (total cholesterol >5.0 mmol/l, low density lipoprotein (LDL)-cholesterol >3.0 
mmol/l), diabetes mellitus, atrial fibrillation (permanent or paroxysmal), current smoking and 
daily alcohol intake.  
 
Fasting blood samples were collected and analysed, heart rate and blood pressure examined, 
and ECG performed. Waist and hip circumferences, weight and height were measured, and 
waist-to-hip-ratio and BMI calculated. Smoking habits and alcohol use were recorded.  
 
Cognitive instruments included in the study 
 The MMSE (standard, 30-point) 
 The Clock Drawing Test  
 The Trail Making Test A and B (TMT A and B)  
 The 10 word test (max score 40) including delayed recall 
 Figures from Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)  
 Ullevaal Aphasia Screening (UAS)  
 
227 patients 
The TOAST study 
209 ischemic 
cerebrovascular 
disease 
The intervention 
study 
195 patients able 
to perform the 
TMT A and the 10 
word test 
The MCI/dementia 
study 
208 patients with 
IQCODE ≤3.44 
The WML study 
227 patients 
174 cerebral infarctions 
36 TIA 
17 cerebral haemorrhage 
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The Clock Drawing Test was dichotomized into correct or incorrect answers (5 versus ≤4 
according to Schulman (135)). TMT B was interrupted after 5 minutes, but we allowed the 
patients to continue past 5 minutes if they insisted. 
 
No clear cut-off exists for the IQCODE in post-stroke samples. A cut-off of 3.44 minimizes 
the probability of including patients with a pre-morbid MCI (142). Information-based 
instruments can be used to complement the diagnostic process.  
 
The assessments for cognitive functioning were performed on day 3-7 during the hospital stay 
and at follow-up.  
 
4.2.2 Assessments at 3 and 6 months. 
Fasting blood samples were collected and analysed, heart rate and blood pressure examined, 
and ECG performed. Waist and hip circumferences, weight and height were measured, and 
waist-to-hip-ratio and BMI calculated. Smoking habits and alcohol use were recorded. We 
also recorded self-reported physical activity in minutes per week and took a brief diet 
anamnesis.  
 
4.2.3 Assessments at the 12 month follow-up 
Again, fasting blood samples were collected and analysed, heart rate and blood pressure 
examined, and ECG performed. Waist and hip circumferences, weight and height were 
measured, and waist-to-hip-ratio and BMI calculated. Smoking habits and alcohol use were 
recorded. We also recorded self-reported physical activity in minutes per week and took a 
brief diet anamnesis.  
 
The patients performed a global cognitive screening equivalent to the screening at baseline, 
extended with figures from ADAS-cog and screening for aphasia using the UAS, and 
collected a history of memory and behavioural changes. Neurological and functional 
measurements were performed using NIHSS, mRS and Barthel ADL-index. Supplementary 
investigations included MRI of the brain, colour duplex of the precerebral arteries and, 
whenever possible, lumbar puncture for examination of neurodegenerative biomarkers in the 
cerebrospinal fluid. 
 
4.3. Baseline characteristics 
All patients were recruited during their stay in the acute stroke unit.  
 
Classification of stroke subtype was made according to the patients’ etiological diagnosis 
(The TOAST classification) and according to the severity and topographical location of the 
ischemic lesion (the OSCP classification). The main characteristics of the patients are shown 
in Table 8. 
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Table 8. Baseline characteristics, n=227 
Variable  N (%) if not other ways 
Demographics Male 115 (50.7) 
 Mean age, years (SD) 72.7 (12.2) 
 Less than nine years of education 55 (24.2) 
Cerebrovascular Cerebral infarction 174 (76.7) 
 TIA 36 (15.9) 
 Cerebral haemorrhage 17 (7.5) 
Risk factors Hypertension 135 (59.5) 
 Hyperlipidaemia 124 (54.6) 
 Diabetes 27 (11.9) 
 Cigarette smoking (present) 51 (22.5) 
 Coronary heart disease 53 (23.3) 
 Atrial fibrillation 75 (33.0) 
 BMI>25 126 (55.5) 
TOAST classification Large vessel disease 24(11.4) 
 Cardioembolic disease 66 (31.4) 
 Small vessel disease 66 (31.4) 
 Stroke of undetermined etiology 54 (25.7) 
Topography Right hemisphere 85 (37.4) 
 Left hemisphere 115 (50.7) 
 Cerebellum/brainsteam 27 (11.9) 
Assessments NIHSS day one, median (IQR) 2.0 (1.0-5.0) 
 NIHSS at discharge, median (IQR) 1.0 (0-2.0) 
 BI, median (IQR) 20.0 (18.0-20.0) 
 mRS, median (IQR) 1.0 (0-2.0) 
Cognitive function IQCODE, mean (SD)(n=224) 3.10 
 MMSE, mean (SD)(n=214) 25.66 
 TMT A, mean  (SD)(n=192) 74.5 
 TMT B, mean (SD)(n=162) 157.4 
 10 word test immediate recall, mean 
(S )( 203)
21.2 
 10 word test, delayed recall , mean 
(S )( 201)
4.2 
TIA=Transient Ischemic Attack; Hyperlipidemia=total cholesterol >5 mmol/l or LDL-
cholesterol >3 mmol/l; LDL=Low Density Lipoprotein; Coronary Heart Disease=previous 
myocardial infarction or present angina pectoris; BMI=body mass index; TOAST= The Trial 
of Org 10172 in Acute Stroke Treatment classification; IQR=Interquartile range; BI=Barthel  
Activities of Daily Living Index; mRs=modified Rankin scale; IQ code=the Informant 
Questionnaire on Cognitive Decline in the Elderly; MMSE= Mini Mental State Examination; 
TMT A= the trail making test A; TMT B= the trail making test B 
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4.4 Methods in the TOAST study, paper 1. 
The TOAST study is based on baseline data. 
 
The diagnosis of stroke and classifications according to the TOAST criteria (Table 9) were 
based on the history of symptoms and their acute presentation, clinical examination and 
cerebral CT scans. This investigation included repeated ECG, NIHSS and blood samples as 
well as additional examination with color duplex images of precerebral arteries (in search of 
large vessel disease) and TTE/TTE (in search of cardio embolic disease). Patients with either 
no probable etiology or more than one potential cause were classified as stroke of 
undetermined etiology. 
 
Table 9. Modified TOAST classification. 
 
 Clinical signs Radiological signs Supplemetary 
investigations 
Large vessel disease Signs of affection of 
the cortex (aphasia, 
apraxia and 
visuospatial 
disturbance, and 
present no neglect 
phenomena or visual 
field defects), 
subcortex, 
cerebellum or 
brainsteam.   
Lesion on CT or 
MRI> 1.5cm in 
cortex, subcortex, 
cerebellum or 
brainstem compatible 
with the symptoms.  
 
No signs on CT or 
MRI* 
Duplex or 
arteriographic signs 
of a significant 
(>50%) stenosis or 
occlusion of the 
internal carotid artery 
or middle cerebral 
artery on the 
symptomatic side 
Cardio embolic 
disease 
Signs of affection of 
the cortex (aphasia, 
apraxia and 
visuospatial 
disturbance, and 
present no neglect 
phenomena or visual 
field defects), 
subcortex, 
cerebellum or 
brainsteam.   
Lesion on CT or 
MRI> 1.5cm in 
cortex, subcortex, 
cerebellum or 
brainstem compatible 
with the symptoms. 
 
No signs on CT or 
MRI* 
Paraclinical signs of 
a source of cardiac 
embolism, on ECG, 
TTE or TEE** 
Small vessel disease A lacunar syndrome, 
either characterized 
by pure motor stroke, 
pure sensory stroke, 
sensomotor stroke, 
ataxic hemiparesis or 
the dysarthria-clumsy 
hand syndrome. 
Lesions on CT or 
MRI should be less 
than 1.5 cm 
 
No signs on CT or 
MRI* 
No large vessel 
disease or cardio 
embolic disease 
identified in color 
duplex of precerebral 
arteries or in 
ECG/TTE/TEE 
*Stroke patients with a clinical stroke syndrome without a corresponding lesion on brain 
imaging were classified according to the clinical presentation and paraclinical findings.  A 
clinical presentation of a lacunar syndrome (see above), with no signs of large vessel disease 
or cardio embolic disease, was diagnosed as small vessel disease. Stroke syndromes with 
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signs of cortical affection but without a source of an embolus were classified as stroke of 
undetermined etiology.   
**The most frequent cardio embolic sources are atrial fibrillation, prosthetic heart valves, 
recent myocardial infarction, dilated cardiomyopathy, intracardiac tumours, rheumatic mitral 
stenosis and infective endocarditis. A patent foramen ovale (PFO) without any other source of 
embolism was classified as cardio embolic disease according to Warlow el al (207).   
 
All but one patient were examined with a precerebral colour duplex scan and all patients with 
an ECG at admittance and on day 1. 92 (44%) had a cerebral MRI and 85 (41%) an 
echocardiography performed. The routines of our hospital require that a CT scan should be 
carried out in all patients in the acute setting, and MRI in selected patients. Patients with 
cortical symptoms and no source of embolism on ECG or echocardiography were monitored 
with a 24-hour ECG.  All paraclinical assessments were performed during the stay or within 
14 days if the patients had an early discharge. Patients below 60 years with no findings on 
routine ECG, echocardiography or precerebral duplex scan, and selected patients with cortical 
symptoms without a source of an embolus, went through a screening for thrombophilia. The 
same patients, in total 13, were assessed with a TEE. 
 
4.5 Methods in the intervention study, paper 2  
This is a randomized, evaluator-blinded, controlled trial with two parallel groups. The study 
physician and nurse were blinded to the allocation. The study was registered with 
Clinicaltrials.gov (NCT00506818). 
 
At discharge from the index stay, the patients were randomized to conventional care in the 
primary care setting or intensive risk factor intervention in the outpatient clinic. Block 
randomization (block size of 20) was performed by a study nurse blinded to the patients’ 
clinical data. The stroke physician was blinded to the results of cognitive tests performed 
before the intervention. The consensus group were blinded to the randomization.  
 
In the intervention study, the patients able to perform the TMT A and the 10 word test were 
randomized. All survivors were examined after 12 months. 
 
4.5.1 Intervention 
Patients in the intervention group were invited to the outpatient clinic for a consultation with 
the study stroke nurse and physician three and six months post-stroke. Information was given 
regarding the importance of changing lifestyle in order to preserve brain health. Medical 
treatment was optimized for the same purpose. Tailored advice was given to the patients 
regarding risk factor management, and a treatment plan was sent to the general practitioner 
(GP).  
 
The intervention was mainly based on recommendations regarding secondary prevention after 
stroke (100;114). Every known risk factor was treated until target: blood pressure ≤140/90, 
total-cholesterol ≤5.0 mmol/l, LDL-cholesterol ≤3.0 mmol/l, HbA1c≤7.0 %, homocysteine 
≤15 μmol/l, and BMI≤25. The patients were offered smoking-cessation courses, and 
encouraged to perform regular moderate physical activity. Advice regarding diet rich in fruit, 
vegetables and fish, low-fat dairy products and less sugar was given. In addition, patients 
were advised not to use alcohol excessively.  
 
The targets are listed in Table 10.  
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Pharmacological intervention included, in addition to antiplatelet agents or warfarin if 
indicated, antihypertensives, statins, antidiabetics and vitamin B complex including folic acid. 
The control patients received treatment as usual by their GPs.  
 
Table 10. Multifactorial risk factor intervention 
 
TARGET  GOAL  
Hypertension  <140/90  
Lipids  Cholesterol <5 mmol/l, 
LDL-cholesterol <3 
mmol/l  
Homocysteine  <15 μmol/l  
Smoking  Courses to quit 
smoking  
Diabetes  HbA1c <7,0 %  
Physical activity  30 minutes at least 3 
times a week  
Overweight  BMI <25 
Alcohol  Excessive use is not 
recommended  
Diet  Fruits, vegetables, low-
fat dairy products, fish  
LDL= low density lipoprotein-cholesterol; BMI= body mass index 
 
4.5.2 Outcomes in the intervention study 
The primary outcomes were changes in TMT A and the 10 -word test from baseline to one 
year post-stroke. The secondary outcomes were diagnoses of dementia or MCI one year post-
stroke. After the trial, an expert panel consisting of two neurologists (BF and BT) and one 
geriatrician (ARØ) reviewed the clinical data. A diagnosis of MCI or dementia was based on 
the results of cognitive assessments and supplementary investigations. MCI was diagnosed 
according to the Petersen criteria and dementia according to the DSM-IV criteria. The panel 
was blinded to allocation. 
 
4.6 Methods in the dementia/MCI study, paper 3 
4.6.1. Evaluation of cerebral MRI 
The MRI scans where examined for possible atrophy of the medial temporal lobe and vascular 
changes. A consensus group, blinded to the allocation, diagnosed cognitive impairments and 
dementia and performed the sub-classification.    
 
Cerebral atrophy was measured as MTLA and graded from 0 to 4. MTLA grade 0=no 
atrophy; MTLA 4=highest degree of atrophy. MTLA 0-1 is considered a normal value.  
WMH were quantified with a semi-automated method, and results were given in total WMH 
volume (mL).  
 
4.6.2 Sub-classification of cognitive impairments post-stroke 
Sub-classification was made using all available information in a novel method in order to 
separate persons with a vascular cause of dementia or MCI from those with a 
neurodegenerative disease.  
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For both dementia and MCI, we based our sub-classification on i) MRI findings of vascular 
and degenerative changes in the brain, ii) the results of biomarkers in cerebrospinal fluid 
(CSF) and iii) the patients’ clinical cognitive profile and vascular risk factors. Consequently, 
radiological findings of WMH without MTLA were classified as vascular disease, while 
MTLA without WMH was interpreted as being of a degenerative origin. A combination of 
WMH and MTLA was diagnosed as mixed vascular and degenerative disease. Thus, isolated 
WMH had a large impact on a diagnosis of vascular dementia and vascular MCI, whereas 
isolated MTLA had a large impact when a diagnosis of degenerative dementia or degenerative 
MCI was made. Whenever biomarkers in the CSF were present, pathological values of tau 
protein, phosphorylated tau protein or beta-amyloid peptide supported a diagnosis of 
degenerative disease. Predominantly cortical symptoms (memory-impairment, affected 
visuospatial function, aphasia, apraxia or neglect) were, when not caused by a cerebrovascular 
lesion, considered to be compatible with degenerative disease, whereas predominantly sub-
cortical symptoms (affecting executive functioning) were interpreted as being most likely of 
vascular origin (123;208). Vascular changes without corresponding subcortical symptoms 
were interpreted as mixed disease.  
 
This resulted in six sub-groups: degenerative dementia or degenerative MCI, vascular 
dementia or vascular MCI, and mixed degenerative and vascular dementia or MCI. Thus, the 
etiological sub-classification was not determined by the use of standardized criteria such as 
the DSM- IV or ICD-10, but rather by using clinical and paraclinical assessments. This 
method is based on the presumption that post-stroke MCI must also have a defined cause, 
since there is a coexistence of vascular lesions and AD pathology in vascular cognitive 
impairment. Diagnoses were made in consensus meetings by two senior neurologists (BF and 
BT) and one senior geriatrician (ARØ).  
 
4.7 Methods in the WML study, paper 4  
We used the same methods as in the dementia/MCI study for evaluation of WML and MTLA. 
 
The outcome variables were the cognitive test performances on TMT B, 10 word test and 
clock drawing test. The tests were chosen in order to evaluate different cognitive domains, 
although single tests may measure more than one specific cognitive function. The 10 word 
test is a measure of memory impairment. The Clock Drawing Test primarily measures 
visuospatial functions, while the TMT B measures executive functioning.  
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5. Statistics 
Statistical analyses were performed with the Statistical Package for Social Science (SPSS), 
version 18.0. 
 
For the TOAST study, statistical analyses were performed using table analyses and bivariate 
and multiple logistic regression. The vascular risk factors were dichotomized into present or 
not present according to recommendations from the American Heart Association (100) and 
the European Stroke Initiative Recommendation from 2003 (114).  
 
For the intervention study, the differences between treatment groups were estimated using 
linear regression analyses (ANCOVA), with one year measurements as dependent variable 
and treatment group and baseline measurements as independent variables. We used the 
Pearson chi-squared test to analyze categorical outcomes. For analyses of primary end points, 
we used complete-case-analyses that included data for patients having both baseline and 12-
month values. All randomized patients were also included in an intention-to-treat analysis by 
imputing missing values as no change from baseline to follow-up. 
 
In the MCI/dementia study, we used table analyses. 
 
In the WML study, the associations between the cognitive test performances (outcome 
variables) and WMLs (explanatory variable) were studied using linear regression (TMT B and 
the 10 word tests) and logistic regression (the Clock Drawing Test).  
 
Table 11 shows the different statistical analyses used in the different sub-studies. 
 
Table 11. Statistical methods used in the sub studies 
 
Sub study Statistical methods 
TOAST study Table analyses and bivariate and multiple logistic regression 
The intervention study Linear regression analyses (ANCOVA), complete-case-analysis 
The dementia/MCI study Table analyses. 
The WML study Linear regression and logistic regression 
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6. Ethical considerations 
The study was approved by the Regional Committee for Ethics in Medical Research and by 
the Data Protection Authorities. All patients gave their written informed consent before 
inclusion. First-degree relatives gave consent on behalf of patients with reduced capacity. 
This procedure was approved by the Ethics Committee. 
 
When the research project was introduced in the stroke unit, the staff became more focused on 
giving the patients the best medical and personal care including information. This may have 
led to a better total care, both for patients included in the study and patients hospitalized after 
the end of the inclusion. 
 
In the present study, we focused on both cognitive symptoms and secondary prevention. 
We introduced a visit for the stroke patients in the outpatients’ clinic three months post-stroke 
with focus on secondary prevention, cognitive impairments and further rehabilitation. This 
was a clinical consultation with both a stroke physician and a dedicated stroke nurse, spending 
longer time with a more holistic profile. Motivation for lifestyle changes included awareness 
of the patients’ preferences. After the study, the three months post-stroke control was 
incorporated in routine clinical practice at our hospital. 
 
Awareness and knowledge regarding post-stroke cognitive impairments, their mechanisms 
and possible preventing strategies are of importance, both for the patients involved and for 
future patients, and these positive effects of the study overweighed the extra effort. We hope 
that focus on cognition and individualized secondary prevention including information 
regarding lifestyle changes in stroke patients, will become a part of the daily routine in stroke 
units. 
 
The most possible harmful or painful procedure introduced in the present study was lumbar 
puncture.  However, only volunteers without oral anticoagulation were asked to take the 
examination of neurodegenerative biomarkers in the cerebrospinal fluid. Only one suffered 
headache after the procedure, with spontaneous recovery. In addition, some patients could 
find the continued encouragement to change lifestyle irritating. 
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7. Abstracts of papers included in the thesis 
 
Risk factors for and incidence of subtypes of ischemic stroke 
 
Background  
The TOAST classification divides patients with ischemic stroke into five subgroups according 
to the presumed etiological mechanism. The aims of the present study were to evaluate the 
distribution of the different etiological stroke subtypes in a hospital-based sample of stroke 
patients, and to investigate the association between important risk factors and stroke subtypes. 
 
Methods  
A total of 210 patients with a first-ever ischemic stroke admitted to the stroke unit of Asker 
and Baerum Hospital in Norway between February 2007 and July 2008 were enrolled in the 
study. Information on vascular risk factors was collected at admittance, examination of 
neurological deficits was carried out during their stay, and classification was made according 
to the TOAST criteria. 
 
Results 
According to the TOAST classification, 24 (11.4 %) of the patients suffered from large vessel 
disease, 66 (31.4%) from cardioembolic disease, 66 (31.4%) from small vessel disease and 54 
(25.7%) from a stroke of undetermined etiology. The presence of hyperlipidemia and atrial 
fibrillation varied significantly between the different subtypes. In multivariate analyses, 
hyperlipidemia [odds ratio (OR) 2.46, 95% confidence interval (CI) 1.32-4.60] and current 
smoking (OR 2.06, 95% CI 1.04-4.08) were the only variables that were related to small 
vessel disease. 
 
Conclusions  
Small vessel disease was observed more frequently and large vessel disease less frequently 
than previously reported. Small vessel disease was significantly associated with 
hyperlipidemia and current smoking. Our study supports the view that the etiology of lacunar 
strokes is multifactorial. 
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Multifactorial vascular risk factor intervention to prevent cognitive impairment after 
stroke and TIA:  A 12- month randomized controlled trial. 
 
Objectives 
There is increasing evidence that vascular risk factor control not only prevents stroke, but also 
reduces the risk of dementia. We aimed to investigate whether better treatment of vascular 
risk factors, through a multifactorial intervention program, reduces the incidence of cognitive 
symptoms one year after stroke and TIA in a hospital-based study of first-ever stroke patients 
without cognitive decline prior to the stroke. 
 
Materials and methods 
Patients suffering their first-ever stroke were included in this randomized, evaluator-blinded, 
controlled trial with two parallel groups. Baseline examination included extensive assessment 
of exposure to vascular risk factors and cognitive assessments regarding memory, attention 
and executive function. After discharge, patients were allocated to either intensive vascular 
risk factor intervention or care as usual. The primary endpoints were changes in TMT A and 
10 word test from baseline to 12 months follow-up.  
 
Results 
195 patients were randomized. The difference between groups in Trail Making Test A, 
adjusted for baseline measurements, was 3.8 seconds (95% confidence interval (CI): -4.2 to 
11.9; p=0.35) in favour of the intervention group. The difference between groups in the 10 
word recall test was 1.1 words (95% CI: -0.5 to 2.7; p=0.17) in favour of the intervention 
group. We did not observe any differences in the secondary outcomes of incident dementia or 
mild cognitive impairment (MCI).  
 
Conclusions 
We could not demonstrate cognitive effects of an intensive risk factor intervention at one year 
post-stroke. Longer follow-up and a more heterogeneous study sample might have lead to 
larger effects. More effective methods for managing the risk of further cognitive decline after 
stroke are needed. 
ClinicalTrials.gov, number NCT00506818. 
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Incidence and Subtypes of MCI and Dementia 1 Year after First-Ever Stroke in Patients 
without Pre-Existing Cognitive Impairment  
 
Background 
Post-stroke dementia is defined as any dementia occurring after stroke, and includes vascular, 
degenerative and mixed dementia. The aim of this study was to assess the incidence of 
dementia and mild cognitive impairment (MCI) one year after stroke in a population free from 
pre-stroke cognitive decline, and to investigate the different aetiological subtypes of post-
stroke dementia and MCI, using a novel method of sub-classification in order to separate 
vascular causes of MCI or dementia from neurodegenerative disease.   
 
Methods 
All patients with a first-ever stroke and TIA admitted to the stroke unit of Asker and Bærum 
Hospital were invited. After 12 months, dementia and MCI were diagnosed. Sub-
classification was made using MRI findings, the results of biomarkers in cerebrospinal fluid 
and the patients’ clinical cognitive profile. 
 
Results 
36 (19.6%) patients developed dementia during the first year after stoke and 69 (37.5%) 
developed MCI.  Fourteen (13.3%) were diagnosed as suffering from degenerative cognitive 
disease, 34 (32.4%) from vascular cognitive disease, and 57 (54.3%) from mixed disease. 
 
Conclusion 
Fifty-seven percent suffered from cognitive impairment one year after stroke and only one 
third from isolated vascular cognitive disease. Post-stroke cognitive impairment is complex 
with a high coexistence of vascular and degenerative changes.    
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Impact of White Matter Lesions on Cognition in Stroke Patients Free from Pre-Stroke 
Cognitive Impairment – A One-Year Follow-Up Study 
 
Background 
Post-stroke cognitive impairment and dementia may be caused by pure vascular, pure 
degenerative or mixed disease. The relation between post-stroke cognitive impairment and the 
combination of vascular pathology and degenerative changes is less evaluated. We aimed to 
evaluate the associations between white matter lesions (WMLs) and patient performance 1 
year after stroke on tests of executive functioning, memory and visuospatial function, adjusted 
for the effects of lifestyle and disease-related factors, including medial temporal lobe atrophy 
(MTLA). 
 
Methods 
Patients with a first-ever stroke or transient ischemic attack were invited to participate in the 
study. The associations between the cognitive test performances and WMLs were studied 
using linear regression [Trail Makin Test B (TMT B) and 10 word tests] and logistic 
regression (Clock Drawing Test). 
 
Results 
In total, 199 patients completed the follow-up. The TMT B (p=0.029) and 10 word test 
(p=0.014) were significantly associated with WMLs; however, the Clock Drawing test 
(p=0.19) was not. The TMT B (p=0.018) and the 10 word test (p≤0.001) were both 
significantly associated with MTLA. 
 
Conclusion 
Impaired executive functioning and memory are significantly associated with WMLs and 
MTLA. The mechanisms explaining post-stroke cognitive impairment are multifactorial, 
including different types of vascular pathology and coexisting vascular and degenerative 
changes.   
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8. General discussion 
The present study involves different aspects of cognitive impairment and dementia after 
stroke and TIA. We wanted to focus on preventive strategies, risk factors and mechanisms 
involved in post-stroke cognitive impairment. This study is designed with cognitive 
impairment as the outcome. We have tried to give attention to the importance of assessment 
of various cognitive symptoms, possible etiological mechanisms and individualized 
preventive strategies including vascular risk factor management. Prevention of recurrent 
stroke and vascular diseases will improve the patients’ outcome post-stroke. We hypothesized 
that cognitive impairment could be prevented as well. However, whether optimal management 
of vascular risk factors will prevent decline or improve cognitive function post-stroke, 
requires further evaluation in new research projects.  
 
We have shown that cognitive impairment post-stroke are frequent, evaluated 12 months after 
the cerebrovascular event. Cognitive impairment post-stroke is due to a mixture of 
degenerative and vascular changes, and these changes seem to overlap and synergize to 
increase the risk of cognitive impairment. Sub-classification of dementia and MCI after stroke 
showed that less vascular and more degenerative changes contribute to cognitive impairment 
one year after the first cerebrovascular event. This may explain why the impact of vascular 
risk factor management on post-stroke cognition is limited the first year post-stroke. 
 
We recommend the use of neuroimaging and CSF biomarkers in the etiological evaluation of 
post-stroke cognitive impairment for detection of vascular changes and atrophy of brain. An 
etiological diagnosis ensures individualized and targeted prevention and treatment. Our 
findings regarding WML and its association with both memory and executive dysfunction 
may indicate a vascular contribution to mechanisms involved in trigging cerebral atrophy 
post-stroke. In addition, pre-stroke asymptomatic degenerative processes may progress to a 
symptomatic stage after the stroke.  
 
In ischemic stroke, we observed a different distribution between the different stroke sub types. 
There may be a shift towards more small vessel disease and cardio embolic disease but less 
large vessel disease. More patients will survive their first stroke, and, therefore, we need to 
have more focus on cognitive function and rehabilitation of the patients. The original lacunar 
hypothesis included hypertension and diabetes, but our findings indicate that other vascular 
risk factors including hyperlipedimia and current smoking may contribute to the risk of small 
vessel disease. All known risk factors should be treated until target post-stroke in order to 
prevent recurrent stroke and possibly even further cognitive decline.  
 
8.1 Methodological considerations 
8.1.1 Patients 
The patients in the present study were included consecutively and prospectively. Admittance 
to the stoke unit were unselected regarding the clinical condition, as even patients with very 
severe neurological impairments were admitted to the stroke unit.  
 
By excluding patients with pre-stroke cognitive impairments and including only first-ever 
stroke patients, the actual brain burden was easier to assess. Only three patients opposed 
inclusion, indicating a representative sample from the stroke unit. 
 
Due to the intervention, only patients who survived the acute phase and with a life expectancy 
of more than one year were included. As a result of this, the most severe cases were not 
included. This may have influenced the distribution regarding the TOAST classification and 
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further, the proportion of patients with cognitive impairment. In addition, patients suffering 
from TIA were included, and in this group, cognitive impairment may develop even more 
slowly. 
 
The participants in this study are highly educated, have excellent access to medical care and 
have a rather healthy lifestyle. This may have influenced the result of the intervention study 
and the distribution between TOAST subtypes.  
 
The use of a high IQCODE cut-off may have lead to inclusion of patients with pre-stroke 
cognitive impairment. In addition, the retrospective assessment with the IQCODE may be 
biased.  
 
The study was designed as an intervention study, and may therefore not be ideal regarding the 
other sub studies. However, due to the non-significant result of the intervention, we assumed 
that the randomization did not influence the other sub studies. 
 
8.1.2 Methods 
In the stroke unit, a standardized protocol for diagnosis, observation, acute treatment, 
including prevention of complications, and early rehabilitation were followed, consistent with 
national and international standards. A dedicated stroke physician examined all patients, and a 
CT scan, standard blood samples, NIHSS and ECG registration were carried out in all patients 
at arrival in the hospital. In this sense, the quality of the diagnostic procedures performed in 
the stroke unit, was satisfactory.  
 
We used the clinical TIA diagnosis without evidence of focal brain lesions on neuroimaging. 
MRI scan in the acute setting is continuously more available, and will in the future give a 
more precise diagnosis of stroke/TIA and a better etiological stroke classification. 
 
In the TOAST study, we failed to establish a clear etiological diagnosis in nearly 25% of the 
patients, mainly due to the fact that stroke may have more than one etiology. Only 13 patients 
had a TEE performed, and none of the echocardiography scans detected aortic plaques. The 
TOAST classification requires a broad detection of etiological mechanisms, and we have used 
a modified TOAST classification due to the clinical setting with MRI in 47% of the cases. 
The association between risk factors and etiological sub groups was compared within the 
stroke group, not with controls free from cerebrovascular disease. 
 
We used cognitive tests available in our stroke unit, based on the assumption that cognitive 
deficits after stroke affect memory, executive function, attention, language and visuospatial 
function. There is a lack of standardization of screening tools for cognitive deficits from both 
vascular and degenerative origin. To screen and grade cognitive status, more reliable tools are 
needed. In addition, the cognitive assessments are performed rather early in the acute phase, 
and assessments in a more stable phase may have varied less. Finally, strategic and greater 
vascular lesions in the acute phase of stroke may cause irreversible injuries, leaving a smaller 
proportion available for intervention. 
 
The choice of primary endpoints can be debated. TMT A and 10 word test were chosen as the 
primary outcomes in order to assess different cognitive domains. In addition, we wanted 
simple and fast tests that are easy to use in clinical practice. Previous studies regarding post-
stroke cognitive impairment have included only patients able to complete comprehensive 
neuropsychological examinations and not patients with aphasia, and as a consequence, by 
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excluding those with larger strokes, this may have led to an underestimation of cognitive 
deficits. TMT A was preferred as an outcome due to the number able to complete the test and 
the association between attention and post-stroke function. Results for TMT B were also 
included in the analyses since we used affected executive function as part of vascular 
cognitive impairments. The ideal test for detecting post-stroke cognitive impairment is 
lacking. However, using the TMT A and 10 word test as the end points may have reduced the 
ability to discriminate the effect of the intervention.  
 
The use of biomarkers in patients with cognitive impairment can improve diagnostic 
accuracy, both in the memory clinic and the follow-up of post-stroke patients. In the present 
study, more patients should have been encouraged to have a lumbar puncture for CSF-
markers. Further, the consensus group for dementia/MCI was highly qualified with long 
clinical practice. The evaluation of MRI scans regarding WML and MTLA was performed by 
dedicated radiologists and a neurologist, the latter using a software to measure diffusion 
parameters.  
 
MRI in the acute phase can be used to identify chronic vascular disease and silent brain 
infarcts, all contributing to sub clinical vascular disease pre-stroke, less brain reserve and 
more vulnerability for cognitive decline. However, under half of the patients had a MRI scan 
in this phase.   
 
Although a single test measures more than one specific function, we chose tests that were able 
to assess the different domains and to indicate vascular or degenerative origins. The screening 
battery chosen to identify cognitive impairments can be debated and may lead to 
simplification in a complex field. Still, the diagnoses of dementia and MCI are based on 
clinical examination and medical history, and cognitive tests in the clinical setting must 
reflect the clinical symptom expression. 
 
The assessments of neurological, functional and cognitive impairments used in the study, 
have been included in the daily routine in our stroke unit, and are today part of the standard 
examination.  
 
8.1.3 The intervention 
The intervention program was easy to communicate, well tolerated and is also now a part of 
the routine in the outpatient clinic. Focus on a healthy lifestyle and motivation to lifestyle 
changes are included in the stroke unit, in addition to focus on cognitive deficits.  
 
The intervention program was based on available knowledge and recommendations in 2006. 
Today, the intervention program would have been even stricter. The blood pressure should 
have been treated to more normal values and the LDL to ≤2.0 (209). Physical activity is 
recommended every day, and even walking 2 hours per week is reported to lower the risk of 
stroke with 30 % in women compared to those who do not (210). Further, focus should be put 
on reduction of waist-hip-ratio and prevention of diabetes. There are some evidence for 
treatment of elevated homocysteine (211), but more studies are needed for recommending 
therapy with folic acid with or without vitamine B 12 (212).  
 
Despite knowledge, it is hard to get people to increase their cardiovascular fitness. Most 
healthcare professional have limited experience and experience in guidance in exercise 
programs for stroke-survivors. The patients will benefit from counseling on participation in 
physical activity and exercise training. More specific registrations of diet and physical 
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activities should have been made and we did not evaluate the care given by the patients’ GP. 
Awareness of their risk factors and motivation for lifestyle changes were, in motivated 
patients, taken care of by the patients’ GP. This homogeneity may decrease the difference 
between the groups in the intervention study.  
 
8.1.4 Statistics 
Some negative results may be due to low statistical power and to short follow-up time. 
Both vascular and degenerative dementias develop over several years, and the observation 
period in our study might have been too short. In addition, the cognitive assessments may 
have varied less if performed in a more stable phase, 1-2 month post-stroke. Finally, the effect 
of the intervention may have been too optimistic. 
 
8.2 The TOAST study 
The TOAST classification is a commonly used classification system that is based on the 
etiology of ischemic stroke.  
 
This classification requires extensive investigations, including colour duplex of precerebral 
arteries and transcranial duplex, to indentify large vessel disease. Cardio embolic disease can 
be diagnosed in the acute setting when atrial fibrillation, a mechanical heart valve or an acute 
myocardial infarction is present. However, other causes of cardio embolic disease and large 
vessel disease, such as patent foramen ovale or atherosclerotic plaque formation in the 
ascending aorta, cannot be diagnosed unless TEE is performed.  
 
There is an observed change between different stroke subtypes towards more small vessel 
disease. Lacunar stroke resulting from small vessel disease has a more favorable outcome 
than other etiologies, but frequently leads to cognitive impairment. Due to better stroke-
survival, the proportion of stroke survivors and patients with cognitive impairments will 
increase. 
 
The lacunar hypothesis was based on autopsy findings in a very few patients, and has been 
under discussion for several years (213).  
 
8.3 The intervention study 
Modification of multiple risk factors through a combination of comprehensive lifestyle and 
appropriate pharmacological therapy is recommended for prevention of recurrent stroke in 
stroke survivors (107). We hypothesized that this should include prevention of cognitive 
impairments post-stroke as well. However, we were not able to confirm this hypothesis.  
 
A proportion of post-stroke cognitive impairments may be reversible. Large strokes, 
especially TACI and even PACI and larger cerebral hemorrhages cause irreversible brain 
damage. Intensive vascular risk factor management may slow the progression of chronic small 
vessel disease (WML), and prevent silent brain infarctions, preserving cognition over several 
years. The first year post-stroke, degenerative pathology, more than vascular pathology, may 
affect cognition and therefore, the timing of evaluation of the prevention strategy was not 
ideal. Subgroup analyses and longer follow-up can give us answers to these questions. 
 
Intention-to-treat analysis is a strategy for the analysis of RCTs that compares patients in the 
groups to which they were originally randomly assigned. However, due to missing data, there 
is a need to impute results from missing data. In different RCTs, however, this approach is 
often inadequately described and inadequately applied, leading to different methodological 
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quality. The authors of RCTs should describe the handling of deviations and discuss the 
potential effect of any missing response (214). 
 
In the intention-to-treat analysis in our study, we imputed data in the manuscript as indicating 
no change from baseline (Table 12). This is a rather conservative scenario. A significant result 
was available imputing data in favour of the intervention (scenario 4). No consensus exists 
about how missing response should be treated in intension-to-treat analyses, indicating that 
we could have used this scenario. However, patients dropping out of the intervention may 
behave more like the control group.  
 
Table 12. Intention-to-treat analysis.  
 
 N (contr./int)  Difference (95% CI)  p-value  
Complete case     
TMT A  81/80  -3.8 (-11.8 to 4.2)  0.35  
10 word test  89/83  1.1 (-0.46 to 2.7)  0.17  
Scenario 1     
TMT A  97/98  -7.2 (-15.6 to 1.3)  0.095  
10 word test 97/98  0.83 (-0.61 to 2.3)  0.26  
Scenario 2     
TMT A  97/98  -7.7 (-15.8 to 0.36)  0.061  
10 word test 97/98  0.87 (-0.63 to 2.4)  0.25  
Scenario3     
TMT A 97/98  1.5 (-7.3 to 10.3) 0.73 
10 word test 97/98  -0.47 (-2.1 to 1.1) 0.56 
Scenario 4     
TMT A 97/98  -15.9 (-24.9 to -7.0) 0.001 
10 word test 97/98  2.3 (0.77 to 3.8) < 0.001 
Scenario 1: All missing = no change from baseline to 12 months  
Scenario 2: All missing = mean change from baseline to 12 months  
Scenario 3: Extreme case favoring control  
   Missing control = 2*mean positive change from baseline  
   Missing intervention = 2*mean negative change from baseline  
Scenario 4: Extreme case favoring intervention  
   Missing control = 2*mean negative change from baseline  
   Missing intervention = 2*mean positive change from baseline  
 
Lifestyle changes include smoking cessation, overweight reduction, physical activity, 
cognitive activity, a healthy diet and mild to moderate alcohol use. Identification of vascular 
risk factors did not necessarily lead to lifestyle changes. Adherence to lifestyle changes are 
challenging. More effective methods of managing vascular risks in these patients are needed, 
including more specific training programs and dietary advice. Further, controls in the 
hospital’s outpatient clinic, with focus on risk factors and compliance, may motivate and 
commit the patients to the individualized preventive program.   
 
In the present study, the intervention was well tolerated, even among the oldest patients. The 
intensive vascular risk factor management is easy to communicate to the patient, and 
adherence to the intervention program can be followed, both in the outpatient clinic and by 
the GP.  
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8.4 The dementia/MCI study 
The spectrum of ischemic changes in the brain is large, encompassing large cortical strokes, 
through identifiable lacunes, to white matter changes. The combination of AD and VaD is 
common in a post-stroke population, making mixed dementia the most common type of 
dementia. Our findings support a multifactorial model for the process leading to post-stroke 
cognitive impairments, including different subtypes. Alzheimer type pathology and vascular 
pathology appear to be common, and may interact in causing cognitive decline, but the impact 
of cerebrovascular lesions on cognitive impairment and dementia needs to be further 
elucidated. Stroke may trigger or unmask the neurodegenerative process (215), or the vascular 
burden may progress and worsen the cognitive status after stroke (216).  
 
The novel method for sub classification was based on the assumption that if dementia post-
stroke has a distinct etiology, MCI must have one too. In order to give proper intervention for 
preventing further decline in cognition, the mechanisms involved must be considered. This 
sub classification may be used directly in treatment and prevention of cognitive impairment. 
However, the method is not validated or evaluated. In addition, the information used for 
classification depended on clinical information and supplementary investigations. The use of 
biomarkers is, however, under discussion. 
 
The method requires biomarkers including MRI, and most hospitals do not have radiologists 
specifically competent in evaluating MTLA and WML. However, the methods are available 
and possible to incorporate when evaluating the MRI. We recommend that patients with 
cognitive symptoms post-stroke also have their MRI evaluated regarding WML and MTLA 
for a correct diagnosis and appropriate prevention.   
 
Distinction between MCI and dementia in post-stroke cognitive impairments is of importance, 
especially for recommendations of prevention, prognosis, treatment and care-level. The 
impairments are delicate in the sense that they are not automatically uncovered when 
performing neurological examination or during observation of ADL functions. MCI requires a 
generally intact ADL function in addition to cognitive impairments that are insufficient to be 
defined as dementia. Recognizing MCI may contribute to an early diagnosis of dementia, 
since MCI patients are at increased risk of developing dementia and a more rapid rate of 
cognitive decline (217).  
 
Post-stroke cognitive impairments are related, in addition to the stroke lesion, to other 
characteristics that may have been present pre-stroke: WML, MTLA, silent infarcts and pre-
stroke cognitive decline (218). Stroke patients seldom have a neuroimaging before the actual 
stroke, but we did not evaluate WML and MTLA on baseline neuroimaging, only on the 
follow-up MRI images. Further, we did not differentiate between WML in different locations, 
only total volume.    
 
8.5 The WML study 
An association between WML and cognitive impairment has been reported earlier (219-221). 
We asked how white matter changes relate to cognition in post-stroke patients, and if WML 
can explain deficits in test performance from clinical practice. The purpose was to relate the 
deficits in cognitive performance to possible etiological mechanisms explaining the findings. 
Results were adjusted for the possible effects of lifestyle and disease-related factors. 
 
Both performances on TMT B and the 10 word test were associated with WML, even after 
adjusting for other explanatory variables. Cognitive impairment of subcortical vascular origin 
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has traditionally been strongly associated with impaired executive functioning, while 
cognitive impairment of cortical, degenerative origin more often affects episodic memory, 
visuospatial function and praxis. Our findings support this way of distinction, but also 
indicate an interaction.  
 
Strokes traditionally do not affect structures known to be involved in memory, but rather 
executive dysfunction and attention. Memory dysfunctions post-stroke may indicate 
disruption of the cerebral network involved in memory. WML may affect the subcortical –
cortical network, leading to cortical disconnection and cognitive decline, again resulting in 
executive dysfunction and impaired memory. In addition, vascular lesions may trigger and 
worsen clinical manifestations of AD (222). WML seems to play an important role in the 
development, not only of vascular, but also of degenerative cognitive impairment and 
dementia. The association observed in our study supports the assumption that cerebral atrophy 
post-stroke may be induced by ischemia and therefore reflects the current cerebrovascular 
lesion. The cerebrovascular event may in addition have an impact on the pre-existing 
degenerative process, and cause an injury that overwhelms the brains’ capacity to 
compensate. Various pathological processes in different degree may lead to a common final 
pathway. 
 
8.6 Final comments 
In our hospital, a visit three months post-stroke with focus on vascular risk factor 
intervention, is now a routine follow up after discharge from the stroke unit. This clinical 
consultation ensures that the patients have an adequate assessment of any cognitive 
impairment and a rehabilitation plan including how to preserve cognition. Risk factor 
detection and management should be focused throughout the acute and rehabilitation phases. 
The adherence to the stroke-prevention program requires both motivated patients and 
physicians, and ideally, a follow-up with focus on the importance of long-term commitments.    
 
In addition to the main study, we have ongoing studies from the multi-disciplinary team. The 
physiotherapists evaluate the patients’ balance related to different stroke sub types and if 
balance disturbances can predict cognitive impairment. The occupational therapists evaluate 
the use of practical assessments for identifying patients with cognitive impairments in the 
acute phase. Two specialized stroke nurses investigate if the etiology is different in young 
adults suffering a stroke.  
 
Stroke and dementia share similar risk factors and the lifetime risk of developing one or both 
is one in three (73). Delaying the onset of dementia, both post-stroke and in general, by 
modifying risks or lifestyle, can decrease the prevalence and the public health burden of 
dementia. Although no definitive interventions have been found that could prevent and slow 
the progression of cognitive impairment in vascular dementia, degenerative dementia or post-
stroke dementia, findings from the literature point to the fact that the treatment of vascular 
risk factors could be favorable. Clinically, stroke and chronic small vessel disease are both 
causes and contributors to cognitive impairment. Vascular risk factor management should 
start early midlife and early in the underlying disease process in order to prevent or delay the 
onset of cognitive impairment. Many stroke survivors are long-term disabled, leading to a 
sedentary lifestyle that limits performance of activities of daily living, increases the risk for 
falls and may contribute to a heightened risk for recurrent stroke and cardiovascular disease. 
The most simple, natural and cheapest ways of preventing a stroke is to exercise regularly. In 
order to preserve cognitive functioning and enhancing quality of life, intellectual activity, 
social engagement, physical activity and treatment of vascular and other diseases are 
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recommended (223;224). Early detection of cognitive deficits and individualized preventive 
strategies may delay onset and progression of cognitive impairment. 
 
8.7 Suggestions for further research 
Better knowledge regarding the impact of the individual risk factor profile may give rise to 
more specific approaches to prevention and therapy after a cerebrovascular event. Additional 
research needs to be conducted in this area.  
 
-We would recommend a longer follow-up period than one year, MRI scans in the acute 
phase, even lower targets for blood pressure and lipids and stronger commitments to programs 
regarding regular physical activity and diet.  
 
-In addition, focus on coping and brain reserve may help both regarding compliance to the 
intervention program, to better understand the discrepancy between brain pathology and the 
clinical presentation and the outcome of the rehabilitation.  
 
-A follow-up study of the same study population, after 6-10 years. 
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9. Conclusions 
 
-The present study indicates that there may be a change in the distribution of the 
different etiological subtypes of ischemic stroke with less large vessel disease and 
more small vessel disease. Further, hyperlipidemia and current smoking seem to be 
stronger associated with small vessel diseases than the other subtypes.  
 
 -We were not able to show that intensive multifactorial vascular risk factor 
intervention preserves cognition one year post-stroke.  
 
-Cognitive impairment post-stroke is frequent and should receive more attention. 
Further, cognitive impairment after stroke is complex and due to heterogenous 
causative factors. There is a coexistence of vascular and degenerative changes in post-
stroke cognitive deficits.  
 
-Both executive dysfunction and affected memory are related to WML post-stroke. 
 
Brain injury from stroke and cerebral vascular disease produce cognitive decline and 
dementia. Further, vascular changes in the brain may worsen the degenerative processes in the 
brain. Identification and treatment of vascular risk factors are of importance to prevent stroke 
and further vascular brain damage. Cognitive reserves built through a healthy lifestyle may 
increase the brain’s capacity to compensate for progressive disease. Each individual can 
prepare for aging through increased awareness of risk factors, regular physical activity and 
intellectual activity. Optimal care in dementia and MCI is multifactorial, and includes early 
diagnosis and multidisciplinary care with educational and non-pharmacological interventions.  
Health research is the best way to bring knowledge regarding vascular contribution to 
cognitive impairment, prevention and treatment.  
 
 
 
 
 
 
 
 
 
“Knowing is not enough; we must apply. Willing is not enough; we must do”.  
Johann Wolfgang von Goethe.  
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Abstract 
 
Objectives 
There is increasing evidence that vascular risk factor control not only prevents stroke, but also reduces 
the risk of dementia. We aimed to investigate whether better treatment of vascular risk factors, through 
a multifactorial intervention program, reduces the incidence of cognitive symptoms one year after stroke 
and TIA in a hospital-based study of first-ever stroke patients without cognitive decline prior to the 
stroke. 
Materials and methods 
Patients suffering their first-ever stroke were included in this randomized, evaluator-blinded, controlled 
trial with two parallel groups. Baseline examination included extensive assessment of exposure to 
vascular risk factors and cognitive assessments regarding memory, attention and executive function. 
After discharge, patients were allocated to either intensive vascular risk factor intervention or care as 
usual. The primary endpoints were changes in TMT A and 10 word test from baseline to 12 months 
follow-up.  
Results 
195 patients were randomized. The difference between groups in Trail Making Test A, adjusted for 
baseline measurements, was 3.8 seconds (95% confidence interval (CI): -4.2 to 11.9; p=0.35) in favour of 
the intervention group. The difference between groups in the 10 word recall test was 1.1 words (95% CI: 
-0.5 to 2.7; p=0.17) in favour of the intervention group. We did not observe any differences in the 
secondary outcomes of incident dementia or mild cognitive impairment (MCI).  
Conclusions 
We could not demonstrate cognitive effects of an intensive risk factor intervention at one year post-
stroke. Longer follow-up and a more heterogeneous study sample might have lead to larger effects. 
More effective methods for managing the risk of further cognitive decline after stroke are needed. 
ClinicalTrials.gov, number NCT00506818. 
 
 
 
 
 
Introduction 
Prevention of cerebrovascular disease may significantly impact the incidence of cognitive decline and 
dementia in the elderly (1;2), and common risk factors are identified for cerebrovascular disease and 
Alzheimer's disease (AD) (3-5). Vascular cognitive impairment refers to the total vascular burden on the 
brain and the effect of vascular disease or lesions on cognition (6). Small vessel disease without stroke, 
including  silent lacunar infarcts, ischemic white matter lesions and incomplete ischemic injury (6), is a 
marker of poor prognosis with increased risk of stroke, cognitive impairment, dementia and death (7). 
However, post-stroke dementia and cognitive impairment are probably due to cumulative effects, 
especially of vascular and degenerative changes in the brain (8;9). Strategies for prevention of post-
stroke cognitive impairment are of importance in order to reduce the consequences of stroke for the 
patients, their relatives and society. 
Previous studies have found different rates of post-stroke dementia;  the prevalence estimated one year 
after stroke varies between 7.4 % in population-based studies of first-ever stroke when patients with 
pre-stroke dementia are excluded, to 41.3 %  in hospital-based cohorts including recurrent stroke and 
pre-stroke dementia (10). Rates regarding post-stroke cognitive impairment differ even more, from 11.6 
to 56.3 % (11), depending on the study population, criteria for cognitive impairment and the time-
interval after stroke for testing. Age, level of education, depression, neurological deficits, stroke subtype, 
and arterial territory correlate with cognitive functioning post-stroke (12). Pre-stroke cognitive 
impairment, progression of small vessel disease, stroke severity and recurrence are known risk factors 
for post-stroke dementia, whereas the influence of various vascular risk factors is under debate. The 
actual stroke lesion seems to be the most important factor in determining the cognitive impairments 
post-stroke (10), where vascular risk factors may enhance the brain`s vulnerability to the stroke lesion.  
Vascular risk factors seem to have a greater impact on delayed post-stroke dementia developing more 
than one year after the cerebrovascular event (13) than on dementia that develops earlier (14). 
However, the mechanisms involved in cognitive impairments after stroke are complex, and a previous 
publication suggests that degenerative mechanisms may be more involved in delayed cognitive 
impairment after stroke than vascular pathology (15). 
As much as 90% of the risk of stroke is found to be attributable to vascular risk factors such as 
hypertension, hyperlipidemia, current smoking, waist-to-hip ratio, diet, physical inactivity, diabetes 
mellitus, alcohol intake, psychosocial stress, depression, cardiac conditions and apolipoprotein B/A1 
ratio (16). In secondary prevention after stroke, the aim is to prevent stroke recurrence as well as to slow 
the progression of brain changes that lead to cognitive impairment and dementia. Evidence-based 
methods for the latter are lacking since most studies after stroke have failed to evaluate cognition as an 
end point.  
Aggressive control of risk factors requires a multifactorial risk factor assessment and treatment (17). The 
motivation to adopt a healthier lifestyle can result from the stroke event itself, but requires an 
individualised intervention including motivation and goal setting(18). Traditionally, there is a gap 
between recommended secondary prevention and observed practice (19). The aim of the present study 
was to investigate whether more intensive treatment of vascular risk factors in patients with first-ever 
stroke or transient ischemic attack (TIA) can influence post-stroke cognitive functioning in patients free 
from cognitive decline prior to the stroke. 
 
 
Methods 
Trial design and randomization 
This is a randomized, evaluator-blinded, controlled trial with two parallel groups.  The study physician 
and nurse were blinded to the allocation. The study was registered with Clinicaltrials.gov 
(NCT00506818). 
At discharge from the index stay, the patients were randomized into conventional care in the primary 
care setting or intensive risk factor intervention in the outpatient clinic. Block randomization (block size 
of 20) was performed by a study nurse blinded to the patients’ clinical data. The stroke physician was 
blinded to the results of cognitive tests performed before the intervention.  
Participants 
All patients with a first-ever stroke or TIA admitted to the stroke unit of Asker and Baerum Hospital 
between February 2007 and July 2008 were invited to participate in the study. Only those patients who 
survived the acute phase (day 7-10) were included. The hospital has a policy of admitting all stroke 
patients directly to the stroke unit, and serves two local municipalities with a total population of 
160,000.  
We excluded patients with subarachnoid haemorrhage, known cognitive decline as indicated by a score 
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or TIA, patients who did not speak Norwegian and patients with a life expectancy less than one year.  
Only patients who were able to perform the Trail Making Test A (TMT A) (21), the 10 word test from the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (22) or both were 
randomized.  
 Assessments 
The primary distinction between ischemic stroke and haemorrhagic stroke was based on neuroimaging 
with cerebral CT and MRI. Vascular risk factors recorded at baseline included treated hypertension 
before hospitalisation, hyperlipidemia (total cholesterol >5.0 mmol/l, low density lipoprotein (LDL)-
cholesterol >3.0 mmol/l), diabetes mellitus, atrial fibrillation (permanent or paroxysmal), current 
smoking and daily alcohol intake.  
At baseline as well as after 12 months, fasting blood samples were collected and analysed, heart rate and 
blood pressure examined, and electrocardiography (ECG) performed. Waist and hip circumferences, 
weight and height were measured, and waist-to-hip-ratio and body mass index (BMI) calculated. 
Smoking habits and alcohol use were recorded.  
Cognitive function was measured with the Mini Mental State Examination (MMSE) (23), clock drawing 
test (24), TMT A and B and the 10 word test. TMT involves multiple cognitive processes. TMT A is a 
measure of focused visual attention and information processing, and is rated in seconds. TMT B is a 
measure of executive functioning. TMT A is a predictor for cognitive ability post-stroke (25). The 10 word 
test is a measure of verbal memory (minimum score zero and maximum 40). These assessments were 
performed on day 3-7 during the hospital stay and at follow-up. Patients with limited neurological 
impairments were assessed on day 3, whereas patients with large strokes were assessed on day 7. 
At the 12-month follow-up, we also recorded self-reported physical activity, performed a global cognitive 
screening and collected a history of memory and behavioural changes. The cognitive screening battery 
contained the MMSE, the clock drawing test, the TMT A and B, figures from Alzheimer's Disease 
Assessment Scale-cognitive subscale (ADAS-cog) (26).  In addition, all patients were screened for aphasia 
using the Ullevaal Aphasia Screening (UAS) (27), a simple test for nurses identifying language disability. 
Supplementary investigations included MRI of the brain, colour duplex of the precerebral arteries and, 
whenever possible, lumbar puncture for examination of neurodegenerative biomarkers in the 
cerebrospinal fluid. 
Intervention 
Patients in the intervention group were invited to the outpatient clinic for a consultation with the study 
stroke nurse and physician three and six months post-stroke. Information was given regarding the 
importance of changing lifestyle in order to preserve brain health. Medical treatment was optimalised 
for the same purpose. Tailored advice was given to the patients regarding risk factor management, and a 
treatment plan was sent to the general practitioner (GP).  
The intervention was based on recommendations regarding secondary prevention after stroke (28;29). 
Every known risk factor was treated until target: blood pressure "#$&*<&?		-cholesterol "X&*?
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offered smoking-cessation courses and encouraged to perform regular moderate physical activity. Advice 
regarding diet rich in fruit, vegetables and fish, low-fat dairy products and less sugar was given. In 
addition, patients were advised not to use alcohol excessively. The targets are listed in Table 1. 
Pharmacological intervention included, in addition to antiplatelet agents or warfarin if indicated, 
antihypertensives, statins, antidiabetics and vitamin B complex including folic acid. The control patients 
received treatment as usual by their GPs.  
Outcomes 
The primary outcomes were changes in TMT-A and the 10 -word test from baseline to one year post-
stroke. The choice of primary endpoints was based on three assumptions:  different cognitive domains 
are involved in post-stroke cognitive impairment (memory, executive dysfunction and attention), simple 
and fast tests used in a clinical acute setting may lead to inclusion of more patients and complex 
neuropsychological tests would have excluded several more patients including those with aphasia. TMT 
A was preferred as an outcome due to the number able to complete the test. However, TMT B was also 
included in the analyses. The secondary outcomes were diagnoses of dementia or mild cognitive 
impairment (MCI) one year post-stroke. After the trial, an expert panel consisting of two neurologists (BF 
and BT) and one geriatrician (ARØ) reviewed the clinical data. A diagnosis of MCI or dementia was based 
on the results of cognitive assessments and supplementary investigations. MCI was diagnosed according 
to the Petersen criteria (30) and dementia according to the ICD 10 criteria (31) with support from the 
DSM-IV TR criteria (32). Dementia was diagnosed when there were impairments in cognitive functioning, 
impairment in activities of daily living and changes in behavior or personality. In MCI, the degree of 
cognitive impairment did not influence on ADL functioning.  Both dementia and MCI diagnoses were 
based on the patients’ history and cognitive performances adjusted for age (TMT A and B, local norms). 
The panel was blinded to allocation. 
Statistics 
Statistical analyses were performed with the Statistical Package for Social Science (SPSS), version 18.0. 
The differences between treatment groups were estimated using linear regression analyses (ANCOVA), 
with one year measurements as dependent variable and treatment group and baseline measurements as 
independent variables. We used the Pearson chi-squared test to analyze categorical outcomes. 
For analyses of primary end points, we used complete-case-analysis that included data for patients 
having both baseline and 12-month values. All patients randomized were also included in an intention-
to-treat analysis by imputing missing values as no change from baseline to follow-up. 
Statistical comparisons of vascular risk factor management utilized the chi-square test. 
Power 
We expected a difference between treatment groups of 10 seconds in the primary outcome of TMT A 
changes from baseline to one year. With an expected standard deviation of 15 seconds for the changes 
(corresponding to a standardized effect size of 0.5), we needed to include 86 patients in each treatment 
arm in order to have 90% power given a 5% significance level. Since the effect estimate was uncertain, 
we aimed for 100 patients in each arm. 
Ethics 
The study was approved by the Regional Committee for Ethics in Medical Research and by the Data 
Protection Authorities. All patients gave their written informed consent before inclusion. First degree 
relatives gave consent on behalf of patients with reduced capacity.  
Results 
Baseline characteristics 
After inviting 253 patients, 250 agreed to participate in the study. Of these, 23 were excluded for the 
following reasons: 12 did not fill the inclusion criteria; _
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?	]{
Norwegian, one had an infarct in the spinal cord, one had suffered a previous TIA, two withdrew their 
consent and one died before signing the consent. The other 11 patients were diagnosed with other 
diseases than stroke. Of the 227 remaining patients, 174 (77%) had a cerebral infarction, 36 (16%) had 
suffered a TIA and 17 (8%) were diagnosed with a cerebral haemorrhage.  
After excluding 32 patients (24 not testable, three persons suffered a new stroke before randomization, 
two did not want randomization, one was diagnosed with a new subdural haematoma, one was 
diagnosed with advanced cancer and one withdrew his consent after advanced heart surgery), 195 
patients were randomized to either the intervention group (n=98) or the control group (n=97). Figure 1 
shows the flow chart. Baseline characteristics are shown in Table 2.  
Adherence to randomization 
During the follow-up period of 12 months, eight patients discontinued and five patients died in the 
intervention group, while four died in the control group. The main reasons for permanent 
discontinuation were tiredness or unwillingness to be reminded about the stroke. One patient 
discontinued after having his driver’s license withdrawn. None dropped out of the intervention program 
due to side-effects of drugs. 85 patients in the intervention group and 93 controls completed the follow-
up.  
Outcomes one year post-stroke (complete-case analysis) 
Results are shown in Tables 3 and 4. 
After one year, the mean TMT A was reduced by 8.1 seconds (95% CI: 0.7 to 15.5) in the control group 
(n=81) and by 17.4 seconds (95% CI: 6.8 to 28.1) in the intervention group (n=80). The difference 
between treatment groups, adjusted for baseline measurements, was 3.8 seconds (95% CI: -4.2 to 11.9; 
p=0.35) in favour of the intervention group. 
The mean increase in 10 word test score was 2.7 words (95% CI: 1.6 to 3.9) in the control group (n=89), 
and 3.9 words (95% CI: 2.8 to 5.1) in the intervention group (n=83). The difference between groups was 
1.1 (95% CI: -0.5 to 2.7; p=0.17) in favour of the intervention group. 
For TMT B, the mean was reduced by 20.5 seconds (95% CI: 0.72 to 40.3) in the control group, (n=68) and 
by 18.5 seconds (95% CI: 3.46-33.6) in the intervention group (n=67). The difference between the 
treatment groups was 5.29 seconds (95% CI: -14.0 to 24.6; p=0.59). TMT B was not a primary outcome, 
but as a measure of executive function it was studied in a post hoc analysis.   
One year post-stroke, 11 (13%) patients in the intervention group and 17 (19%) in the control group had 
developed dementia (p=0.30), while 35 (41%) in the intervention group and 33 (36%) in the control 
group had developed MCI (p=0.50). Combining these two results, 46 (54%) in the intervention group and 
50 (55%) in the control group had developed MCI or dementia (p=0.91). None suffered a recurrent stroke 
during follow-up, but four in the intervention group and one in the control group suffered a TIA.    
Outcomes one year post-stroke (intention-to-treat analysis) 
For this analysis, missing data were imputed so that the additional observations indicated no change 
from baseline. The results are shown in Table 3. The only noticeable change compared with the 
complete-case analyses was a slight increase in between group difference in mean TMT A, although the 
difference remained statistically insignificant (p=0.099). Neither for TMT B did any significant difference 
appear (p=0.97). 
When comparing the groups regarding vascular risk factor management, significantly more patients in 
the intervention group than in the control group reached the target for the intervention regarding 
systolic blood pressure "#$& (59/85 in the intervention group and 50/92 in the control group, p=0.04), 
LDL-cholesterol "&81/85 in the intervention group and 75/93 in the control group, p=0.006) and 
homocysteine"#X (68/82 in the intervention group and 59/91 in the control group, p=0.004). The results 
were nearly significant for total-cholesterol "X& (76/85 in the intervention group and 74/93 in the 
control group, p=0.073) and smoking cessation (10/18 in the intervention group and 6/24 in the control 
group, p=0.061).  Non-pharmacological interventions such as reducing BMI to "[Xand increasing 
physical exercise to over 90 minutes per week were not significantly different between the groups. 
Physical activity in the intervention group was performed 225 minutes/week (SD 224) and 192 
minutes/week (SD 201) in the control group.    
In many stroke patients, cognitive impairments resolve over the first 1-2 months post-stroke, and the 
ideal time for evaluation of stable cognitive outcome would have been at this time. In order to evaluate 
whether this aspect influenced the results, we did a crude 12 months comparison. These analyses 
showed no significant differences between the intervention and control groups, neither in the complete 
case nor in the intention-to-treat analyses. 
Discussion 
We hypothesized that a multifactorial vascular risk factor intervention would reduce the incidence of 
cognitive symptoms one year after stroke. We were not able to confirm this hypothesis. There was an 
observed difference, though not statistically significant, in favour of the intervention group. The negative 
result may be due to insufficient statistical power or selective drop-outs, but this remains speculative 
and should be the focus of further studies. In addition, the possible expected effect of treatment may 
have been too optimistic.  In the intension-to-treat analysis, the power was improved, but imputed data 
for missing values were set to no change, leading to a conservative estimate.  
Both vascular and degenerative dementias develop over several years, and the observation period in our 
study might have been too short. Further, patients suffering from TIA were included, and in this group 
cognitive impairment may develop even more slowly. Strategic lesions and greater vascular lesions in the 
acute phase of stroke may cause irreversible injuries, leaving a smaller proportion available for 
intervention. In addition, degenerative mechanisms, and not vascular pathology, may have greater 
impact on cognition in the first year post-stroke (15). Finally, the baseline assessments were performed 
rather early after the stroke event. If the cognitive assessments had been performed in a more stable 
phase, the results probably would have varied less (33;34). 
At discharge, all patients were given optimal secondary treatment, including antithrombotic and 
antihypertensive therapies as well as statins. Patients in our well-educated sample have good access to 
health care and are aware of their risks. Care for the control group may have been so good that further 
improvements in the intervention group became marginal. Further, persons of lower socio-economic 
status are more likely to have a poor diet, to be overweight, to smoke, and to be sedentary; all these 
factors contribute to higher burdens of vascular risk. Both the risks of stroke and late-life AD are 
associated with a low socio-economic status and a lower educational level (35). The high educational 
level in our sample may thus contribute to a healthier lifestyle including regular physical activity, and 
hence protect against cognitive decline. 
Despite the general knowledge in Western societies regarding vascular risk factors, lifestyle changes are 
challenging. Johnson et al (36) showed that the identification of vascular risk factors did not necessarily 
lead to lifestyle changes. More effective methods of managing vascular risks in these patients are 
needed, including more specific training programs and dietary advice. Maybe the stroke event per se 
makes people more ready to change behaviour, rather than the intervention.  
There are some additional limitations. Only persons able to perform the cognitive tests in the acute 
phase were randomized. Consequently, patients with large cortical strokes were not included in the 
randomization. Patients who died during the follow-up period more often suffered large strokes. Since 
patients with pre-stroke cognitive impairments and previous cerebrovascular events were not included, 
the risk of post-stroke cognitive decline was lower than in the general stroke population. The primary 
outcomes were based on the assumption that vascular cognitive impairment affects attention and 
executive functioning, while AD patients suffer more memory impairments.  The tests may not, however, 
be sensitive enough to show a difference, especially due to the high educational level and relatively short 
follow-up time. Further, TMT A is a quite rough test, and there might have been a possible effect of the 
intervention not detected by this test. Even for TMT B, however, there was no significant difference 
between the groups. The imbalance between the groups regarding sex, age and stroke subtype may 
have influenced the risk for cognitive impairment. The variance in TMT-A within the patient group was 
larger and the difference between the groups smaller than estimated in the power-calculation. A single-
center study cannot automatically be generalized to all stroke populations. The drop-out from the 
intervention group may have influenced the results negatively since persons less motivated for 
structured intervention may have dropped out. The high cut-	
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 CODE may have resulted in 
inclusion of patients with pre-stroke cognitive decline, both due to degenerative and vascular disease. 
Finally, taking part in the study may have altered behavior regardless of group allocation (Hawthorne 
effect).  
This is one of the first studies specifically designed for the prevention of cognitive impairments, and even 
if we did not observe more than a small, non-significant effect, the study is still of importance.  The 
relative contribution of coexisting vascular and neurogenerative pathologies to cognitive decline needs 
to be better defined in order to implement more targeted and specific preventive strategies. This 
includes structured care, combining lifestyle and pharmacological interventions. Further studies should 
also be performed over a longer period of time and use baseline assessments from a stable phase. 
Vascular risk factors and unhealthy behavior present in midlife have a deleterious effect on late-life 
cognition and dementia (37), implying that early vascular risk factor detection and treatment is 
recommended(38). At present, there are no effective guidelines for prevention of cognitive impairments 
in this patient group. 
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 Table 1. Multifactorial risk factor intervention 
 
TARGET  GOAL  
Hypertension  <140/90  
Lipids  Cholesterol <5 mmol/l,  
LDL-cholesterol <3 
mmol/l  
Homocysteine  #XZ*  
Smoking  Courses to quit smoking  
Diabetes  HbA1c <7,0 %  
Physical activity  30 minutes at least 3 
times a week  
Overweight  BMI <25 
Alcohol  Excessive use is not 
recommended  
Diet  Fruits, vegetables, low-
fat dairy products, fish  
LDL= low density lipoprotein-cholesterol; BMI= body mass index 
 
 
 
 
 
 
 
 
Table 2. Baseline characteristics of patients (n=195). Figures are n (%) unless specified otherwise  
Assessment Intervention Control 
Demographics   
Male 45 (46) 59 (61) 
Mean age, years (SD) 72.6 (11.2) 70.6 (13.6) 
Less than nine year of education 19 (19) 25 (26) 
Stroke subtype   
Cerebral infarction 69 (70) 75 (77) 
TIA 23 (24) 12 (12) 
Cerebral haemorrhage 6 (6.1) 10 (10) 
Risk factors   
Hypertension 60 (61) 54 (56) 
Hyperlipidemia 56 (57) 53 (55) 
Diabetes 8 (8.2) 13 (13) 
Cigarette smoking (present) 18 (18) 24 (25) 
Coronary heart disease 21 (21) 26 (27) 
Atrial fibrillation 34 (35) 24 (25) 
Daily alcohol use 21 (21) 17 (18) 
BMI>25 60 (61) 53 (55) 
OCSP classification   
TACI 3 (3.1) 7 (7.2) 
PACI 50 (51) 47 (49) 
LACI 32 (33) 29 (30) 
POCI 13 (13) 14 (14) 
Topography   
Right hemisphere 36 (37) 38 (39) 
Left hemisphere 46 (47) 49 (51) 
Cerebellum/brainsteam 16 (16) 10 (10) 
Assessments   
NIHSS day one, m! 2.0 (0-3)  3.0 (0-3.5)  
	
?! 1.0 (0-2)  1.6 (0-2)  
BI at discharge?! 19 (20-20)  18 (19.25-20)  
mRS at discharge?! 1.0 (0-1)  1.3 (0-2)  
Hyperlipidemia=total cholesterol >5 mmol/l or LDL-cholesterol >3 mmol/l; LDL= Low Density Lipoprotein; Coronary Heart 
Disease=previous myocardial infarction or present angina pectoris; BMI=body mass index; OCSP=Oxfordshire Community Stroke 
Project classification; TACI=Total Anterior Circulation Infarction; PACI=Partial Anterior Circulation Infarction; LACI=Lacunar 
Circulation Infarction; POCI=Posterior Circulation Infarction; NIHSS=National Institute of Health Stroke Scale; BI=Barthel 
		_{\\	
		{		 
 Table 3. Results 
 
 Intervention group Control group Between-group 
difference 
(intervention – 
control) 
Mean (95% CI)* 
 
N 
Baseline 
Mean (SD) 
12 
months 
Mean 
(SD) 
Change 
Mean 
(95% CI) N 
Baseline 
Mean 
(SD) 
12 
months 
Mean 
(SD) 
Change 
Mean 
(95% CI) 
Complete 
case** 
         
   TMT A 80 73.4(68.3) 
55.0 
(38.3) 
-17.4  
(-28.1 to -
6.8) 
81 
63.0 
(36.0) 
55.0 
(28.9) 
-8.1  
(-15.5 to -
0.7) 
-3.8  
(-11.9 to 4.2), 
p=0.35 
   10 word 
test 
83 21.3 (6.9) 
25.3 
(7.4) 
3.9  
(2.8 to 
5.1) 
89 
21.7 
(7.1) 
24.5  
(7.4) 
2.7  
(1.6 to 
3.9) 
1.1 
 (-0.5 to 2.7), 
p=0.17 
Intention 
to treat*** 
         
   TMT A 98 
75.1 
(65.4) 
60.9 
(42.4) 
-14.2  
(-23.0 to 
5.5) 
97 
74.3 
(53.4) 
67.5 
(51.3) 
-6.7 
 (-12.9 to 
-0.6) 
-7.1  
(-15.6 to 1.3), 
p=0.099 
   10 word 
test 
98 21.2 (6.7) 
24.5  
(7.4) 
3.3  
(2.3 to 
4.4) 
97 
21.1 
(7.8) 
23.6  
(8.3) 
2.5 
 (1.4 to 
3.6) 
0.8  
(-0.6 to 2.3), 
p=0.26 
*Adjusted for baseline measurements, using ANCOVA.  
**Includes patients with both baseline and 12 months measurements only. 
*** Missing data imputed as no change from baseline to 12 months. 
 
 
 
  
Table 4. Results, secondary outcomes 
 
 
Secundary outcome 
N (%) 
Intervention 
N=85 
Control 
N=91 
P value 
Dementia 11 (13%) 17 (19%) 0.30 
MCI 35 (41%) 33 (36%) 0.50 
Dementia or MCI 46 (54%) 50 (55%) 0.91 
 
 
 
III
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 Abstract
 Background/Aim: Post-stroke cognitive impairment and dementia may be caused by pure vas-
cular, pure degenerative or mixed disease. The relation between post-stroke cognitive impair-
ment and the combination of vascular pathology and degenerative changes is less evaluated. 
We aimed to evaluate the associations between white matter lesions (WMLs) and patient per-
formance 1 year after stroke on tests of executive functioning, memory and visuospatial func-
tion, adjusted for the effects of lifestyle and disease-related factors, including medial temporal 
lobe atrophy (MTLA).  Methods: Patients with a first-ever stroke or transient ischemic attack 
were invited to participate in the study. The associations between the cognitive test perfor-
mances and WMLs were studied using linear regression [Trail Making Test B (TMT B) and 10-
word test] and logistic regression (Clock Drawing Test).  Results: In total, 199 patients completed 
the follow-up. The TMT B (p = 0.029) and the 10-word test (p = 0.014) were significantly associ-
ated with WMLs; however, the Clock Drawing Test (p = 0.19) was not. The TMT B (p = 0.018) and 
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the 10-word test (p ≤ 0.001) were both significantly associated with MTLA.  Conclusion: Im-
paired executive functioning and memory are significantly associated with WMLs and MTLA. 
The mechanisms explaining post-stroke cognitive impairment are multifactorial, including dif-
ferent types of vascular pathology and coexisting vascular and degenerative changes.
 Copyright © 2012 S. Karger AG, Basel
 Introduction
 Stroke is associated with an increased risk of cognitive impairment and dementia  [1, 2] 
and contributes to cognitive decline in various neurodegenerative dementia disorders  [3] . 
Post-stroke cognitive impairment and dementia may be caused by pure vascular disease, 
pure degenerative disease or the coexistence of vascular and degenerative diseases  [4] . In ad-
dition to evident stroke lesions, post-stroke vascular changes include subcortical white mat-
ter lesions (WMLs), silent lacunar infarctions and cerebral microhemorrhages  [5] . WMLs, 
initially described in 1987  [6] and named leukoaraiosis  [7] , are defined as areas of high signal 
intensity on T 2 -weighted magnetic resonance imaging (MRI) and are related to variable de-
grees of demyelination, axonal loss and gliosis  [8] .
 WMLs are associated with vascular risk factors, especially hypertension and higher 
age  [9] . Further, WMLs are associated with the development of vascular and mixed demen-
tia in patients with mild cognitive impairment  [10] . Elderly patients with severe WMLs are 
at risk of becoming more dependent in activities of daily living  [11] . Severe post-stroke 
WMLs predict cognitive decline  [12] and indicate a higher risk of recurrent stroke  [13] . 
WMLs are present in 11–21% of adults aged around 64 years  [14] , in up to 44% of patients 
with stroke or transient ischemic attack (TIA) and in 50–75% of patients with vascular de-
mentia  [15] .
 Executive and visuospatial dysfunctions are associated with severe WMLs, whereas 
memory and language dysfunctions are only weakly associated with WMLs  [16, 17] . How-
ever, the correlation between specific clinical symptoms and the topographical location of 
WMLs is under debate  [18, 19] . The relation between post-stroke cognitive impairment and 
the combination of vascular pathology and degenerative changes has not been fully exam-
ined.
 Accordingly, we aimed to evaluate the associations between WMLs and patient perfor-
mance 1 year after stroke on tests measuring executive functioning, memory and visuospa-
tial function. Results were adjusted for the possible effects of lifestyle and disease-related 
factors, including medial temporal lobe atrophy (MTLA) as an indicator of possible neuro-
degenerative disease mechanisms.
 Methods
 Participants
 All patients with a first-ever stroke or TIA admitted to the Stroke Unit of Bærum Hos-
pital, Vestre Viken Hospital Trust between February 2007 and July 2008 were invited to par-
ticipate in the study. Only those patients who survived the acute phase the first week were 
assessed. The hospital has a policy of admitting all stroke patients directly to the Stroke Unit. 
It serves two counties with a total population of approximately 160,000 inhabitants.
 We excluded patients with subarachnoid hemorrhage, dementia or mild cognitive im-
pairment diagnosed before stroke onset, a history of cognitive decline or cognitive decline 
as indicated by a score of  6 3.7 on the Informant Questionnaire on Cognitive Decline in the 
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Elderly (IQ-CODE)  [20] , previous stroke or TIA, patients who did not speak Norwegian and 
patients with a remaining life expectancy of less than 1 year as estimated by the treating phy-
sician. The IQ-CODE was filled in by the patient’s spouse, a first-degree relative or a close 
friend. The cut off 3.7 was chosen based on the results of a previous study that reported pre-
stroke cognitive decline with an IQ-CODE score of  6 4.0  [21] and modified to ensure exclu-
sion of pre-stroke dementia.
 Assessments
 The primary distinction between ischemic stroke and hemorrhagic stroke was based on 
neuroimaging with cerebral computer tomography (CT). We used the WHO definition of 
stroke and the clinical diagnosis of TIA based on the acute loss of focal cerebral function 
with symptoms lasting less than 24 h  [22] . TIA patients were included since cognitive impair-
ments in TIA patients may persist beyond the resolution of focal symptoms  [23] .
 Cognitive functioning was measured at baseline and after 12 months using the Mini-
Mental State Examination (MMSE)  [24] , the Clock Drawing Test  [25] , the Trail Making Test 
A and B (TMT A and B)  [26] and the 10-word test including delayed recall from the Repeat-
able Battery for the Assessment of Neuropsychological Status (RBANS) (maximal score 40) 
 [27] . The Clock Drawing Test was dichotomized into correct or incorrect answers (5 vs.  ^  4 
according to Shulman  [25] ). The TMT B was interrupted after 5 min, but we allowed the pa-
tients to continue afterwards if they insisted. All patients tried to perform all tests, including 
the TMT A and TMT B, in the acute phase, but results are only reported from those who 
were able to complete the tests.
 The cognitive assessments were chosen in order to evaluate different cognitive domains. 
The 10-word test is a measure of memory impairment. The Clock Drawing Test primarily 
measures visuospatial functions, while the TMT B measures executive functioning. Cogni-
tive impairment of subcortical vascular origin has traditionally been strongly associated 
with impaired executive functioning, while cognitive impairment of cortical, degenerative 
origin more often affects episodic memory, visuospatial function and praxis. Although sin-
gle tests may measure more than one specific cognitive function, we chose a test battery that 
could assess different cognitive domains.
 Neurological impairment was assessed using the National Institutes of Health Stroke 
Scale (NIHSS)  [28] . The neurological examinations were performed on the first day after ad-
mittance by an experienced stroke physician. The NIHSS was repeated at discharge and at the 
12-month follow-up. We screened for pre-stroke cognitive impairment using the 26-question 
version of the IQ-CODE  [20] , repeated after 12 months. Activities of daily living were assessed 
by the Barthel ADL index  [29] , and global functioning was evaluated by the modified Rankin 
Scale  [29] . Patients with ischemic stroke were classified according to The Trial of Org 10172 
in Acute Stroke Treatment (TOAST) classification  [30] by a stroke physician.
 Patients underwent an MRI of the brain at the 12-month follow-up. Cerebral atrophy 
was measured according to the method first described by Scheltens et al.  [31] . Based on the 
height of the hippocampal formation and the enlargement of the surrounding cerebrospinal 
fluid spaces, the MTLA is graded from 0 to 4 (MTLA grade 0 = no atrophy; MTLA 4 = high-
est degree of atrophy; MTLA 0–1 are considered normal values).
 WMLs were quantified with a semi-automated method in the Nordic lCE Basis Module 
as described earlier  [32] . The manual placement of regions of interest in known white matter 
fiber tracks is a common method to measure diffusion parameters. This software is preferred 
for this purpose, but other programs for diffusion tensor imaging are available  [33] . In the 
fluid-attenuated inversion recovery images, pixel values in the white matter higher than 2 SD 
above the mean pixel value of the respective slices were defined as WMLs. The total WML 
areas in all slices were added together and multiplied with the slice thickness to obtain the 
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total WML volume (ml). In this sample, patients with pencil line lesions along the ventricles 
and non-confluent small subcortical lesions did not have a total WML volume exceeding 1.5 
ml. Moderate and severe lesions may represent subcortical ischemic small vessel disease  [16] . 
 Statistics
 The associations between the cognitive test performances (outcome variables) and 
WMLs (explanatory variable) were studied using linear regression (TMT B and 10-word test) 
and logistic regression (Clock Drawing Test). First, univariate analyses were performed. Sec-
ond, 19 candidate variables were analyzed as possible confounding variables, i.e. age, sex, 
Apo E alleles, MTLA, education, vascular risk factors, etiological subtypes of ischemic stroke, 
neurological deficits as measured by NIHSS and stroke in the left hemisphere (table 2). Only 
predictors assessed at baseline, except for physical activity which was assessed at the follow-
up, were included in the analyses in order to evaluate the effect on cognitive outcomes, 
WMLs and MTLA 12 month after stroke. All explanatory variables with a p value  ! 0.20 in 
unadjusted analyses were included in the multivariate regression models. All variables (ex-
cept for WMLs) with a p value  1 0.05 were thereafter removed from the models, one at a time, 
until the final adjusted models were reached. We assessed the interaction between WMLs 
and MTLA for each outcome using regression models that included WMLs, MTLA and their 
product as explanatory variables. We used all data available for each analysis, which ranged 
from n = 148 in multivariable analyses to n = 197 in univariable analyses.
 Statistical analyses were performed with STATA 11. All significance tests were two-
tailed and performed at the 5% level.
 Ethics
 The study was approved by the Regional Committee for Ethics in Medical Research and 
by the Data Protection Authorities. All patients gave their written informed consent before 
inclusion. First-degree relatives gave consent on behalf of patients with reduced capacity. 
This procedure was approved by the Ethics Committee.
 Results
 Baseline Characteristics
 After inviting 253 patients, 250 agreed to participate in the study. Of these, 23 were ex-
cluded; 12 did not fulfill the inclusion criteria (6 had an IQ-CODE score  6 3.7, 1 did not speak 
Norwegian, 1 had an infarction in the spinal cord, 1 had suffered a previous TIA, 2 withdrew 
their consent and 1 patient died before signing the consent) and 11 patients were diagnosed 
with other disease than stroke.
 Of the 227 remaining patients, 174 (76.7%) had a cerebral infarction, 36 (15.8%) had suf-
fered a TIA and 17 (7.5%) were diagnosed with cerebral hemorrhage. Baseline characteristics 
are listed in  table 1 .
 In total, 199 patients completed the follow-up. Of the 28 patients missing, 19 died and 9 
refused to complete the follow-up period. Further, 182 had an MRI for analysis of WMLs and 
MTLA.
 The estimated associations between WMLs and the tests for different cognitive domains, 
including the potentially confounding variables, are displayed in  table 2 . The cognitive tests 
for executive functioning, memory and visuospatial function after 1 year of follow-up were 
all significantly associated with the degree of WMLs. After fitting multivariable regression 
models including patients’ characteristics, vascular risk factors and stroke characteristics, 
the associations remained statistically significant between the severity of WMLs and the 
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 Table 1. P atients characteristics at baseline and 12 months
 Variable  Baseline 
 (n = 227) 
 12 months 
 (n = 199) 
 Demographics 
 Male gender 115 (50.7) 
 Age, years 72.7812.2 
 Education <9 years 55 (24.2) 
 Stroke subtype 
 Cerebral infarction 174 (76.7) 
 TIA 36 (15.9) 
 Cerebral hemorrhage 17 (7.5) 
 Risk factors 
 Hypertension 135 (59.5) 
 Hyperlipidemia 124 (54.6) 
 Diabetes 27 (11.9) 
 Cigarette smoking (present) 51 (22.5) 
 Coronary heart disease 53 (23.3) 
 Atrial fibrillation 75 (33.0) 
 BMI >25 126 (55.5) 
 TOAST classification 
 Large vessel disease 24 (11.4) 
 Cardioembolic disease 66 (31.4) 
 Small vessel disease 66 (31.4) 
 Stroke of undetermined etiology 54 (25.7) 
 Topography 
 Right hemisphere 85 (37.4) 
 Left hemisphere 115 (50.7) 
 Cerebellum/brain stem 27 (11.9) 
 Assessments 
 NIHSS score on day 1 4.1 (1.0–5.0) 
 NIHSS score at discharge 2.4 (0–2.0) 1.8 (0–1.0) 
 BI score 20.0 (18.0–20.0) 18.6 (19.0–20.0) 
 mRS score 1.0 (0–2.0) 1.3 (1.0–2.0) 
 Cognitive assessments (n) 
 IQ-CODE 3.1080.23 (224) 3.3180.41 (188) 
 MMSE  25.6684.78 (214)  25.8685.8 (194) 
 TMT A 74.5865.0 (192) 63.3848.9 (185) 
 TMT B  157.4894.5 (162)  142.4886.7 (160) 
 10 word-test, immediate recall 21.287.1 (203) 23.688.5 (195) 
 10 word-test, delayed recall 4.282.5 (201)* 5.083.1 (195) 
 V alues denote n (%), median (IQR) or mean 8 SD.
 Hyperlipidemia = Total cholesterol >5 mmol/l or low-density lipoprotein cholesterol >3 mmol/l; Cor-
onary heart disease = previous myocardial infarction or present angina pectoris; BMI = body mass index; 
IQR = interquartile range; BI = Barthel activities of daily living index; mRS = modified Rankin Scale.
 * 15 patients did not complete the delayed recall. This test was introduced a little later in the study. 
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performances on TMT B (p = 0.029) and the 10-word list with immediate recall (p = 0.014), 
but not between WMLs and the Clock Drawing Test (p = 0.19) ( table 2 ).
 In addition, age (p  ! 0.001), MTLA (p = 0.018), diabetes (p = 0.006), NIHSS score on day 
1 (p = 0.017) and small vessel disease as cause of the stroke (p = 0.011) were significantly and 
independently associated with the TMT B, whereas low education (p  ! 0.001), MTLA (p  ! 
0.001), hyperlipidemia (p = 0.011), NIHSS score on day 1 (p = 0.023) and left hemisphere 
 Table 2. R esults of unadjusted and adjusted regression models for all proposed explanatory variables and the three outcomes
Variable 10-word test TMT B Clock Drawing Test
unadjusted adjusted 
(final model)
unadjusted adjusted 
(final model)
unadjusted adjusted 
(final model)
regression 
coefficients
(95% CI)
p value regression 
coefficients
(95% CI)
p value regression 
coefficients
(95% CI)
p value regression 
coefficients
(95% CI)
p value OR estimate 
(95% CI)
p value OR est imate 
(95% CI)
p 
value
WMLs –0.30 
(–0.44, –0.17)
<0.001 –0.16 
(–0.28, –0.03)
0.014 3.50 
(1.83, 5.18)
<0.001 1.75 
(0.18, 3.33)
0.029 1.06 
(1.02, 1.10)
0.003 1.03 
(0.99, 1.07)
0.19
Age –0.24 
(–0.33, –0.14)
<0.001 2.82 
(1.80, 3.84)
<0.001 2.09 
(0.94, 3.23)
<0.001 1.06 
(1.03, 1.09)
<0.001 1.06 
(1.02, 1.10)
0.001
Sex
(male = 0)
–1.17 
(–3.59, 1.25)
0.34 6.12 
(–21.5, 33.7)
0.66 3.59 
(1.97, 6.55)
<0.001 3.26 
(1.62, 6.55)
0.001
Number of Apo E 4 
alleles present overall: p = 0.72 overall: p = 0.10 overall: p = 0.62
1 vs. 0 –0.85 
(–3.80, 2.11)
0.57 –36.7 
(–71.3, –2.10)
0.038 0.01 
(–0.16, 0.18)
0.89
2 vs. 0 2.05 
(–5.49, 9.60)
0.59 –27.3 
(–114, 59.1)
0.53 0.22 
(–0.22, 0.66)
0.33
MTLA 
(2–4 vs. 0–1)
–6.26 
(–8.50, –4.02)
<0.001 –4.51 
(–6.67, –2.35)
<0.001 70.9 
(44.3, 97.5)
<0.001 33.0 
(5.86, 60.1)
0.018 3.76 
(1.96, 7.22)
<0.001
Education 
(≤9 years = 0)
6.55 
(3.73, 9.37)
<0.001 4.83 
(2.32, 7.34)
<0.001 –22.3 
(–57.5, 12.8)
0.21 0.58 
(0.29, 1.16)
0.12
Homocysteine 
(mol/l)
–0.25 
(–0.50, –0.009)
0.042 2.45 
(–0.41, 5.32)
0.093 1.01 
(0.95, 1.07)
0.82
Hypertension
(treated)
–3.07 
(–5.51, –0.63)
0.014 30.7 
(3.52, 57.9)
0.027 1.65 
(0.91, 2.99)
0.10
Hyperlipidemia 4.57 
(2.22, 6.92)
<0.001 2.72 
(0.59, 4.85)
0.013 –38.3 
(–65.5, –11.2)
0.006 0.82 
(0.46, 1.45)
0.49
Diabetes –3.84 
(–7.63, –0.06)
0.047 63.7 
(14.9, 112)
0.011 60.4 
(17.2, 104)
0.006 1.61 
(0.66, 3.92)
0.29
Atrial fibrillation
(at present)
–1.11 
(–3.80, 1.57)
0.41 17.1 
(–13.0, 47.2)
0.26 1.00 
(0.54, 1.88)
0.99
Coronary heart 
disease
–2.23 
(–5.06, 0.61)
0.12 45.5 
(13.7, 77.3)
0.005 0.86 
(0.44, 1.71)
0.68
Cigarette 
smoking (at 
present)
–0.14 
(–3.54, 3.26)
0.94 –5.65 
(–45.1, 33.8)
0.78 0.83 
(0.36, 1.90)
0.65
BMI 0.20 
(–0.11, 0.51)
0.21 –1.47 
(–5.22, 2.29)
0.44 0.91 
(0.84, 0.98)
0.018
Physical activity
(min/week)
0.007 
(0.001, 0.01)
0.017 –0.035 
(–0.10, 0.03)
0.27 0.997 
(0.995, 0.999)
0.007
Diagnosis overall: p = 0.010 overall: p = 0.53 overall: p = 0.13
TIA vs. 
infarction
3.63 
(0.36, 6.90)
0.030 –20.7 
(–57.3, 15.9)
0.27 0.40 
(0.16, 0.98)
0.046
Hemorrhage 
vs. infarction
–3.93 
(–8.17, 0.31)
0.069 0.78 
(–53.4, 54.9)
0.98 0.71 
(0.25, 2.03)
0.53
TOAST (small 
vessel disease = 0)
–2.05 
(–4.67, 0.56)
0.12 30.7 
(2.20, 59.2)
0.035 32.9 
(7.69, 58.0)
0.011 1.15 
(0.61, 2.15)
0.67
NIHSS (score on 
day 1) 
–0.62 
(–0.85, –0.38)
<0.001 –0.28 
(–0.53, –0.04)
0.017 5.33 
(0.54, 10.1)
0.029 5.63 
(1.02, 10.2)
0.017 1.15 
(1.07, 1.23)
<0.001 1.12 
(1.04, 1.22)
0.005
Topographic 
location (left = 0)
3.06 
(0.68, 5.44)
0.012 2.59 
(0.58, 4.59)
0.009 –9.21 
(–36.4, 18.0)
0.50 1.00 
(0.56, 1.77)
1.00
 Apo E = Apolipoprotein E; Hyperlipidemia = total cholesterol >5 mmol/l or low-density lipoprotein cholesterol >3 mmol/l; Coronary heart disease = previous myocar-
dial infarction or present angina pectoris; BMI = body mass index. The values are the regression coefficients for the 10-word test and TMT B (linear regression) and the odds 
ratio for the Clock Drawing Test (logistic regression).  
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stroke (p = 0.012) were significantly and independently associated with the 10-word test. 
Failure on the Clock Drawing Test was significantly associated with increasing age (p = 
0.001), NIHSS score on day 1 (p = 0.005) and female sex (p = 0.001).
 No interaction between WMLs and MTLA was observed for any of the three outcomes 
(all p  6 0.34), indicating that different processes are involved in atrophy and chronic vascu-
lar changes.
 Discussion
 We found that the cognitive tests for both executive functioning (TMT B) and impaired 
memory (10-word test) were significantly associated with WMLs. However, the bivariate as-
sociation between the Clock Drawing Test and WMLs was not statistically significant after 
adjusting for the influence of increasing age, NIHSS score on day 1 and gender.
 The association between deficits in executive functioning and WMLs in stroke patients 
has been reported earlier  [16, 17] and may be due to chronic cerebral small vessel disease with 
endothelial dysfunction, hypoperfusion and affected blood-brain barrier leading to subse-
quent cell injury  [34, 35] . Furthermore, our results also indicate an association between im-
paired memory and WMLs after stroke. This contrasts the traditional belief that memory 
disturbances are less severe in vascular dementia than in Alzheimer’s disease  [36] . Previous 
findings regarding non-memory-related cognitive deficits in association with WMLs diverge 
even more  [19] , and in stroke patients, impaired memory has been related to reduced tempo-
ral lobe functioning  [37] . However, vascular changes in the brain can be associated with ex-
ecutive functioning as well as with impaired memory  [14, 38] , ostensibly due to subcortical 
damage and a disruption of the pathways between gray and white matter. WMLs are related 
to more rapid global functional decline  [39] and, in the post-stroke situation, may contribute 
to cognitive decline and progression of cognitive dysfunction. In addition, we observed an 
association between reduced performance on the 10-word test and stroke in the left hemi-
sphere, indicating cortical damage affecting language and understanding.
 Both reduced executive functioning and impaired memory were significantly associated 
with MTLA, supporting the theory that a degenerative component plays a central role in 
some patients with post-stroke cognitive impairments  [3] . Vascular lesions may amplify the 
effect of existing degenerative pathology or affect beta-amyloid deposits. Further, MTLA, in 
addition to subcortical vascular changes, seems strongly related to post-stroke executive dys-
function. Our findings support the assumption that white matter changes, vascular lesions 
of the brain and Alzheimer’s disease pathology coexist and give rise to an increased risk of 
post-stroke cognitive impairment  [13, 40] .
 We observed an association between some vascular risk factors and cognitive impair-
ment; hyperlipidemia was associated with the 10-word test and diabetes with the TMT B. 
Midlife high cholesterol increases the risk of Alzheimer’s disease later in life  [41] , represents 
a well-known risk for vascular disease  [42] and may indicate a risk for post-stroke cognitive 
impairments of both degenerative and vascular origin, whereas diabetes is one of the tradi-
tional risks for lacunar infarcts  [43] .
 Surprisingly, hypertension was not associated with any of the cognitive tests. Midlife 
hypertension is a risk factor for dementia  [41] as well as for WMLs  [9] . One explanation for 
our finding may be that we only identified treated hypertension, and the hypertension in our 
patients was mostly well controlled before the stroke. Treatment of vascular risk factors in 
patients with cerebrovascular disease may slow the progression of WMLs  [44] and, therefore, 
intensive secondary prevention may contribute to preserve cognitive functioning.
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 Our study has some limitations. We included patients with TIA, and both the incidence 
of cognitive impairment and the WML load are lower in these patients. Limitations also in-
clude the absence of a measure of silent infarcts, microbleeds and global cortical atrophy. In 
addition, WMLs were measured only in volume. A more precise topographical description 
of the lesions could have been even more helpful in understanding the relationship between 
WMLs and cognitive functioning.
 We found that the cognitive tests for both executive functioning (TMT B) and impaired 
memory (10-word test) were significantly associated with WMLs. There was also a signifi-
cant association between impaired executive functioning and memory with MTLA. Our 
findings support the assumption that the mechanisms explaining post-stroke cognitive im-
pairment are multifactorial, including different types of vascular pathology and coexistence 
of vascular and degenerative changes. The relationship between WMLs and MTLA was not 
significant.
 Clinically, it is of importance to determine which patients are at risk of dementia among 
those who survive a stroke. The onset of cognitive impairment may be linked to the initial 
severity of WMLs as well as the pre-stroke degenerative process. This aspect has clinical im-
plications in choosing the most appropriate therapeutic strategy and to start prevention ear-
lier in order to preserve cognition. Treatment requires control of all modifiable risk factors.
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